ClinicalTrials.gg
CompletedNCT02723955Updated Dec 27, 2024Results posted

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

A Phase 1 interventional study of feladilimab (GSK3359609) and GSK3174998 in Neoplasms, sponsored by GlaxoSmithKline. Completed at 28 sites in 9 countries. Open to participants aged 18 Years to 93 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
829
Allocation
Non-randomized
Ages
18 Years to 93 Years
Sex
All
01

Study summary

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • ICOS receptor agonist antibody
  • Pembrolizumab
  • KEYNOTE-478
  • GSK3359609
  • Cohort expansion
  • Dose escalation
  • Dostarlimab
  • Cobolimab
  • Bintrafusp alfa
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 829 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 93 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed, written .
  • Male or female, age 18 to 93 years (at the time consent is obtained).
  • Histological or cytological documentation of an invasive that was diagnosed as locally advanced/ or and is of one of the following tumor types: bladder/urothelial cancer of the upper and lower urinary tract; cervical; colorectal (includes appendix); esophagus, squamous cell; head and neck carcinoma; melanoma; malignant pleural mesothelioma (MPM); non-small-cell lung cancer (NSCLC), prostate; Microsatellite Instability-High/deficient mismatch repair (MSI-H/dMMR) tumor (Part 1B and Part 2B) and Human Papilloma Virus (HPV)-positive or Epstein-Barr (EBV)-positive tumor (Part 1B and Part 2B).
  • Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists; exceptions are in these tumor types in which pembrolizumab single agent may be a standard: NSCLC, head and neck squamous cell cancer (HNSCC), bladder/urothelial cancer, MSI-H/dMMR cancers and melanoma and cervical cancer. In Part 2B pembrolizumab combination expansion cohorts, prior treatment with anti-Programmed cell death protein 1()/ Ligand-1 (L1) may not be required. 1) Participants must not have received more than 5 for advanced disease including both standards of care and therapies. 2) Participants who received prior PD-1/L1 therapy must fulfill the following requirements (Part 1B [except PK/PD cohort]/ Part 2B):a) Have achieved a CR, PR or SD and subsequently had disease progression while still on PD-1/L1 therapy; b) Have received at least 2 doses of an approved PD-1/L1 inhibitor (by any regulatory authority), c) Have demonstrated disease progression as defined by (RECIST) version 1.1 within 18 weeks from the last dose of the PD-1/L1 inhibitor. The initial evidence of disease progression is to be confirmed by a second assessment no less than four weeks from the date of the first documented Progressive Disease (PD) (the confirmatory scan could be the Baseline eligibility scan for this study). 3) In Part 2A 5-fluorouracil (FU)/platinum combination with GSK3359609 and pembrolizumab cohort, participants must not have received prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy given as part of multimodal treatment for locally advanced disease).
  • obtained at any time from the initial diagnosis to study entry; a fresh tumor biopsy using a procedure that is safe for the participant on a lesion not previously irradiated unless lesion progressed will be required if archival tissue is unavailable.
  • Agree to undergo a pre-treatment and on treatment biopsy and have disease amenable to biopsy required in pharmacokinetic (PK) / pharmacodynamics (PD), dose randomized HNSCC, Melanoma dose expansion and Biomarker cohorts..
  • per RECIST version 1.1. Palpable lesions that are not measurable by radiographic or photographic evaluations may not be utilized as the only measurable lesion. Any measurable lesion biopsied at Screening cannot be followed as a target/index lesion unless agreed upon by GlaxoSmithKline (GSK).
  • (ECOG) performance status (PS) 0-1.
  • of at least 12 weeks.
  • Adequate organ function.
  • corrected for heart rate according to Fridericia's formula (QTcF) \<450 milliseconds (msec) or QTcF \<480 msec for participants with bundle branch block.
  • A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test in females of ), and not lactating or reproductive potential agrees to follow one of the options listed in protocol from 30 days prior to the first dose of study medication and until 120 days after the last dose of study treatment.
  • Male participants with female partners of child bearing potential must agree to use one of the methods of specified in protocol from time of first dose of study treatment until 120 days after the last dose of study treatment.
  • Documented HPV/ EBV-positive tumor as determined by a local laboratory for Part 1B and Part 2B pembrolizumab combination viral-positive expansion cohorts only.
  • Documented MSI-H or dMMR-positive tumor as determined by local laboratory for Part 1B and Part 2B pembrolizumab combination MSI-H/dMMR expansion cohorts only.
  • ICOS expression result using an analytically validated immunohistochemistry (IHC) assay by central laboratory for Part 1B biomarker cohort only.
  • Gene expression (GEX) result using an analytically validated method by central laboratory (Part 1B Biomarker Cohort only).
  • PD-L1 combined positive score (CPS) \<1 using the Food and Drug Administration (FDA) approved PD-L1 IHC 22C3 pharmdx assay by central laboratory testing for Part 2B HNSCC PD-L1 CPS \<1 Cohort. Documented test result from FDA approved PD-L1 IHC 22C3 pharmDx assay in local laboratory, if available, may be accepted in lieu of the central laboratory test result.

Exclusion criteria

Exclusion Criteria

  • Prior treatment with the following therapies:

• Anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.

• Part 2B (GSK3359609/pembrolizumab combination): prior pembrolizumab washout is not required.

• Prior radiation therapy: permissible if at least one non-irradiated is available for assessment according to version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least two weeks before start of study drug for radiation of any intended use to the extremities for bone and 4 weeks for radiation to the chest, brain, or visceral organs is required. • therapy within 30 days or 5 half-lives of the investigational product (whichever is shorter). At least 14 days must have elapsed between the last dose of investigational agent and the first dose of study drug is administered.

  • Prior or autologous bone marrow transplantation or other solid organ transplantation.
  • Toxicity from previous anticancer treatment
  • Invasive or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the participant was definitively treated, has been disease-free for \<=2 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer.
  • Central nervous system (CNS) metastases, with the following exception: • Participants who have previously-treated , are asymptomatic, and have no requirement for at least 14 days prior to first dose of study drug. Participants with carcinomatous meningitis or are excluded regardless of clinical stability.
  • Received transfusion of blood products (including or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, recombinant erythropoietin) within 14 days prior to the first dose of GSK3359609.
  • Major surgery \<=4 weeks before the first dose of study treatment. Participants must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment.
  • Active disease that has required systemic treatment within the last two years (i.e., with use of disease modifying agents, corticosteroids or drugs). Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Concurrent medical condition requiring the use of systemic immunosuppressive medications within 7 days before the first dose of study treatment. Physiologic doses of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the participant is on a stable dose.
  • Condition requiring treatment with strong inhibitors/inducers of cytochrome p (CYP) 450 3A4 within 7 days prior to first dose of chemotherapy (requirement applies to participants enrolled to Part 2 chemotherapy combination with docetaxel).
  • Active infection requiring systemic therapy, known infection, or positive test for active infection or active infection.
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment).
  • Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction that required surgery.
  • Receipt of any within 4 weeks prior to first dose of study treatment.
  • Recent history of allergen desensitization therapy within 4 weeks of starting study treatment.
  • History of severe to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
  • History or evidence of cardiac abnormalities.
  • History of (current and past) idiopathic pulmonary fibrosis, pneumonitis (for past pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia. Note: post-radiation changes in the lung related to prior radiotherapy and/or asymptomatic radiation-induced pneumonitis not requiring treatment may be permitted if agreed by the investigator and Medical Monitor.
  • Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other condition that could interfere with the participant's safety, obtaining , or compliance to the study procedures.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
829 participants (actual)

Study arms

  • Experimental
    Part 1A: Dose escalation feladilimab (GSK3359609)

    Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.

    Drug: feladilimab (GSK3359609)

  • Experimental
    Part 1B: Expansion feladilimab (GSK3359609)

    Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.

    Drug: feladilimab (GSK3359609)

  • Experimental
    Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.

    Drug: feladilimab (GSK3359609) · Drug: Pembrolizumab

  • Experimental
    Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.

    Drug: feladilimab (GSK3359609) · Drug: GSK3174998

  • Experimental
    Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)

    Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.

    Drug: feladilimab (GSK3359609) · Drug: Docetaxel · Drug: Pemetrexed · Drug: Paclitaxel plus Carboplatin · Drug: Gemcitabine plus Carboplatin · Drug: Fluorouracil (5-FU) plus carboplatin or cisplatin

  • Experimental
    Part 2B: Expansion-feladilimab (GSK3359609)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.

    Drug: feladilimab (GSK3359609) · Drug: Pembrolizumab

  • Experimental
    Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.

    Drug: feladilimab (GSK3359609) · Drug: Dostarlimab

  • Experimental
    Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.

    Drug: feladilimab (GSK3359609) · Drug: Dostarlimab · Drug: Cobolimab

  • Experimental
    Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)

    Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.

    Drug: feladilimab (GSK3359609) · Drug: Bintrafusp alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).

    Time frame: Up to approximately 367 weeks

  2. Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)

    DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

    Time frame: Up to 28 days

  3. Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

    Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  4. Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  5. Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

    Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  6. Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  7. Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

    Time frame: Up to approximately 367 weeks

  8. Part 1A: Number of Participants With Dose Modifications of Feladilimab

    Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab.

    Time frame: Up to approximately 367 weeks

  9. Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

    Time frame: Up to approximately 367 weeks

  10. Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)

    DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

    Time frame: Up to 28 days

  11. Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

    Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  12. Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  13. Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

    Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  14. Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  15. Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

    Time frame: Up to approximately 367 weeks

  16. Part 2A: Number of Participants With Dose Modifications of Feladilimab

    Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab

    Time frame: Up to approximately 367 weeks

Secondary outcomes

  1. Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

    Time frame: Up to approximately 367 weeks

  2. Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

    Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  3. Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%

    Time frame: Up to approximately 367 weeks

  4. Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

    Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  5. Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  6. Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

    Time frame: Up to approximately 367 weeks

  7. Part 1B: Number of Participants With Dose Modifications of Feladilimab

    Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab.

    Time frame: Up to approximately 367 weeks

  8. Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

    Time frame: Up to approximately 367 weeks

  9. Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

    Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  10. Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  11. Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

    Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

    Time frame: Baseline (Day 1) and up to approximately 367 weeks

  12. Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

    Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

    Time frame: Up to approximately 367 weeks

  13. Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

    Time frame: Up to approximately 367 weeks

  14. Part 2B: Number of Participants With Dose Modifications of Feladilimab

    Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab.

    Time frame: Up to approximately 367 weeks

  15. Part 1A: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  16. Part 1A: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

    Time frame: Up to approximately 367 weeks

  17. Part 1A: Overall Survival (OS)

    OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

    Time frame: Up to approximately 367 weeks

  18. Part 1A: Progression-free Survival (PFS)

    PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1

    Time frame: Up to approximately 367 weeks

  19. Part 1A: Time to Overall Response (TTR)

    TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  20. Part 1A: Duration of Response (DOR)

    DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  21. Part 2A: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  22. Part 2A: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

    Time frame: Up to approximately 367 weeks

  23. Part 2A: Overall Survival (OS)

    OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

    Time frame: Up to approximately 367 weeks

  24. Part 2A: Progression-free Survival (PFS)

    PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  25. Part 2A: Time to Overall Response (TTR)

    TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  26. Part 2A: Duration of Response (DOR)

    DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  27. Part 1B: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  28. Part 1B: Disease Control Rate (DCR)

    DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

    Time frame: Up to approximately 367 weeks

  29. Part 1B: Overall Survival (OS)

    OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

    Time frame: Up to approximately 367 weeks

  30. Part 1B: Progression-free Survival (PFS)

    PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  31. Part 1B: Time to Overall Response (TTR)

    TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  32. Part 1B: Duration of Response (DOR)

    DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  33. Part 2B: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  34. Part 2B: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

    Time frame: Up to approximately 367 weeks

  35. Part 2B: Overall Survival (OS)

    OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

    Time frame: Up to approximately 367 weeks

  36. Part 2B: Progression-free Survival (PFS)

    PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

    Time frame: Up to approximately 367 weeks

  37. Part 2B: Time to Overall Response (TTR)

    TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 367 weeks

  38. Part 2B: Duration of Response (DOR)

    DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1

    Time frame: Up to approximately 367 weeks

  39. Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab

    Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours POST EOI; week 1; week 2; Pre-dose and 0.5 hours POST EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours POST EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33

  40. Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33

  41. Part 2A: Ctau of Pembrolizumab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93

  42. Part 2A: AUC (0-504h) of Pembrolizumab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93

  43. Part 2A: Cmax and Ctau of GSK3174998

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93

  44. Part 2A: AUC (0-504 h) of GSK3174998

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93

  45. Part 1B: Cmax and Ctau of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45

  46. Part 1B: AUC (0-504 h) of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45

  47. Part 2B: Cmax and Ctau of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

  48. Part 2B: AUC (0-504 h) of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

  49. Part 2B: AUC (0-1008 h) of Feladilimab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

  50. Part 2B: Cmax and Ctau of Pembrolizumab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

  51. Part 2B: AUC (0-504h) of Pembrolizumab

    Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

    Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

  52. Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  53. Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  54. Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  55. Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  56. Part 2A: Number of Participants With Positive Results in ADA in GSK3174998

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  57. Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  58. Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  59. Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  60. Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab

    Serum samples collected and tested for the presence of ADA with a screening assay.

    Time frame: Up to approximately 367 weeks

  61. Part 1A: Receptor Occupancy of Feladilimab

    Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

    Time frame: Up to approximately 367 weeks

  62. Part 2A: Receptor Occupancy of Feladilimab

    Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

    Time frame: Up to approximately 367 weeks

  63. Part 1B: Receptor Occupancy of Feladilimab

    Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

    Time frame: Up to approximately 367 weeks

  64. Part 2B: Receptor Occupancy of Feladilimab

    Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

    Time frame: Up to approximately 367 weeks

07

Results

Posted Dec 27, 2024

Participant flow

Escalation Phase
Participant flow — Escalation Phase
MilestonePart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgCrossover: Fela 0.100 mg/kg + Pembro 200 mgCrossover: Fela 0.300 mg/kg + Pembro 200 mgCrossover: Fela 1.000 mg/kg + Pembro 200 mgCrossover: Fela 3.000 mg/kg + Pembro 200 mgCrossover: Fela 24 mg + Pembro 200 mgCrossover: Pembro 200 mg
Started11272425152770005558111114164363613221400000000000000
Completed0000010000001101300000101310000000000000000
Not completed1127242415277000445781114164263510211400000000000000
Withdrew: Death11271817112130002456671313324317130100000000000000
Withdrew: Lost to follow-up0000021110001000120121001130100000000000000
Withdrew: Physician decision0000020000000000000000000020000000000000000
Withdrew: Withdrawal by subject0000111100001000100000020100100000000000000
Withdrew: Participants were crossed over or were re-treated following progression0000522430000000000000000000000000000000000
Withdrew: Site closed0000000000000001020010003131100000000000000
Expansion Phase
Participant flow — Expansion Phase
MilestonePart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgCrossover: Fela 0.100 mg/kg + Pembro 200 mgCrossover: Fela 0.300 mg/kg + Pembro 200 mgCrossover: Fela 1.000 mg/kg + Pembro 200 mgCrossover: Fela 3.000 mg/kg + Pembro 200 mgCrossover: Fela 24 mg + Pembro 200 mgCrossover: Pembro 200 mg
Started0000000003911559000000000000000001425544234651000000
Completed00000000013300000000000000000114230310000000
Not completed0000000003811256000000000000000001324142204341000000
Withdrew: Death000000000256948000000000000000001220231172331000000
Withdrew: Lost to follow-up00000000004100000000000000000119210000000000
Withdrew: Physician decision0000000000000000000000000000001100000000000
Withdrew: Withdrawal by subject0000000002100000000000000000008400010000000
Withdrew: Participants were crossed over or were re-treated following progression000000000103610000000000000000003000000000000
Withdrew: Site closed0000000001260000000000000000008422000000000
Crossover/ Re-treatment Phase
Participant flow — Crossover/ Re-treatment Phase
MilestonePart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgCrossover: Fela 0.100 mg/kg + Pembro 200 mgCrossover: Fela 0.300 mg/kg + Pembro 200 mgCrossover: Fela 1.000 mg/kg + Pembro 200 mgCrossover: Fela 3.000 mg/kg + Pembro 200 mgCrossover: Fela 24 mg + Pembro 200 mgCrossover: Pembro 200 mg
Started000000000000000000000000000000000000011942211
Completed0000000000000000000000000000000000000003000
Not completed000000000000000000000000000000000000011939211
Withdrew: Death000000000000000000000000000000000000011432210
Withdrew: Lost to follow-up0000000000000000000000000000000000000004000
Withdrew: Physician decision0000000000000000000000000000000000000011001
Withdrew: Site closed0000000000000000000000000000000000000042000

Outcome measures

PrimaryPart 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Any AEs1127222413216
Any SAEs0012684121
PrimaryPart 1A: Number of Participants With Dose Limiting Toxicity (DLT)

DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)000001000
PrimaryPart 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Hypoglycemia , Grade 0, Grade 1000014110
Hypoglycemia , Grade 0, Grade 2000010000
Hypoglycemia , Grade 1, Grade 0000000100
Hypoglycemia , Grade 4, Grade 2000000000
Hypoglycemia , Grade 4, Grade 3000000000
Hyperglycemia , Grade 0, Grade 101011057111
Hyperglycemia , Grade 0, Grade 2000213210
Hyperglycemia , Grade 0, Grade 4000000000
Hyperglycemia , Grade 1, Grade 0000000100
Hyperglycemia , Grade 1, Grade 2000111101
Hyperglycemia , Grade 1, Grade 3000001000
Hyperglycemia , Grade 2, Grade 3000000000
Hyperglycemia , Grade 2, Grade 4000000000
Hyperglycemia , Grade 3, Grade 0000000000
Hyperglycemia , Grade 3, Grade 1000000000
Hyperglycemia , Grade 3, Grade 2000001000
Hyperglycemia , Grade 3, Grade 4000000000
Hyperglycemia , Grade 4, Grade 0000000000
Hyperglycemia , Grade 4, Grade 1000000000
Hyperglycemia , Grade 4, Grade 2000000000
Hyperglycemia , Grade 4, Grade 3000000000
Hypoalbuminemia , Grade 0, Grade 1101365691
Hypoalbuminemia , Grade 0, Grade 2000061101
Hypoalbuminemia , Grade 0, Grade 3000000000
Hypoalbuminemia , Grade 0, Grade 4000000000
Hypoalbuminemia , Grade 1, Grade 0000010000
Hypoalbuminemia , Grade 1, Grade 2000004110
Hypoalbuminemia , Grade 1, Grade 3000000000
Hypoalbuminemia , Grade 1, Grade 4000000000
Hypoalbuminemia , Grade 2, Grade 0000000000
Hypoalbuminemia , Grade 2, Grade 1000000000
Hypoalbuminemia , Grade 2, Grade 3000000000
Hypoalbuminemia , Grade 2, Grade 4000000000
Hypoalbuminemia , Grade 3, Grade 0000000000
Hypoalbuminemia , Grade 3, Grade 1000000000
Hypoalbuminemia , Grade 3, Grade 2000000000
Hypoalbuminemia , Grade 3, Grade 4000000000
Hypoalbuminemia , Grade 4, Grade 0000000000
Hypoalbuminemia , Grade 4, Grade 1000000000
Hypoalbuminemia , Grade 4, Grade 2000000000
Hypoalbuminemia , Grade 4, Grade 3000000000
AP Increased, Grade 0, Grade 1000246432
AP Increased, Grade 0, Grade 2000010010
AP Increased, Grade 0, Grade 3000000010
AP Increased, Grade 0, Grade 4000000000
AP Increased, Grade 1, Grade 0000000000
AP Increased, Grade 1, Grade 2000011010
AP Increased, Grade 1, Grade 3000000100
AP Increased, Grade 1, Grade 4000000000
AP Increased, Grade 2, Grade 0000000000
AP Increased, Grade 2, Grade 1000010000
AP Increased, Grade 2, Grade 3000100010
AP Increased, Grade 2, Grade 4000000000
AP Increased, Grade 3, Grade 0000000000
AP Increased, Grade 3, Grade 1000000000
AP Increased, Grade 3, Grade 2000000000
AP Increased, Grade 3, Grade 4000010000
AP Increased, Grade 4, Grade 0000000000
AP Increased, Grade 4, Grade 1000000000
AP Increased, Grade 4, Grade 2000000000
AP Increased, Grade 4, Grade 3000000000
ALT Increased, Grade 0, Grade 1000130350
ALT Increased, Grade 0, Grade 2000000100
ALT Increased, Grade 0, Grade 3000002000
ALT Increased, Grade 0, Grade 4000000010
ALT Increased, Grade 1, Grade 0000011000
ALT Increased, Grade 1, Grade 2000020000
ALT Increased, Grade 1, Grade 3000000000
ALT Increased, Grade 1, Grade 4000000000
ALT Increased, Grade 2, Grade 0000000000
ALT Increased, Grade 2, Grade 1000000000
ALT Increased, Grade 2, Grade 3000000000
ALT Increased, Grade 2, Grade 4000000000
ALT Increased, Grade 3, Grade 0000000000
ALT Increased, Grade 3, Grade 1000000000
ALT Increased, Grade 3, Grade 2000000000
ALT Increased, Grade 3, Grade 4000000000
ALT Increased, Grade 4, Grade 0000000000
ALT Increased, Grade 4, Grade 1000000000
ALT Increased, Grade 4, Grade 2000000000
ALT Increased, Grade 4, Grade 3000000000
AST Increased, Grade 0, Grade 1000254391
AST Increased, Grade 0, Grade 2000002100
AST Increased, Grade 0, Grade 3000001000
AST Increased, Grade 0, Grade 4000000010
AST Increased, Grade 1, Grade 0000001000
AST Increased, Grade 1, Grade 2000000000
AST Increased, Grade 1, Grade 3000010000
AST Increased, Grade 1, Grade 4000000000
AST Increased, Grade 2, Grade 0000000000
AST Increased, Grade 2, Grade 1000000000
AST Increased, Grade 2, Grade 3000010100
AST Increased, Grade 2, Grade 4000000000
AST Increased, Grade 3, Grade 0000000000
AST Increased, Grade 3, Grade 1000000000
AST Increased, Grade 3, Grade 2000000000
AST Increased, Grade 3, Grade 4000000000
AST Increased, Grade 4, Grade 0000000000
AST Increased, Grade 4, Grade 1000000000
AST Increased, Grade 4, Grade 2000000000
AST Increased, Grade 4, Grade 3000000000
Blood Bilirubin Increased, Grade 0, Grade 1000010101
Blood Bilirubin Increased, Grade 0, Grade 2000011100
Blood Bilirubin Increased, Grade 0, Grade 3000000010
Blood Bilirubin Increased, Grade 0, Grade 4000000000
Blood Bilirubin Increased, Grade 1, Grade 0000000100
Blood Bilirubin Increased, Grade 1, Grade 2000010000
Blood Bilirubin Increased, Grade 1, Grade 3000010000
Blood Bilirubin Increased, Grade 1, Grade 4000000000
Blood Bilirubin Increased, Grade 2, Grade 0000000000
Blood Bilirubin Increased, Grade 2, Grade 1000000000
Blood Bilirubin Increased, Grade 2, Grade 3000000000
Blood Bilirubin Increased, Grade 2, Grade 4000000000
Blood Bilirubin Increased, Grade 3, Grade 0000000000
Blood Bilirubin Increased, Grade 3, Grade 1000000000
Blood Bilirubin Increased, Grade 3, Grade 2000000000
Blood Bilirubin Increased, Grade 3, Grade 4000000000
Blood Bilirubin Increased, Grade 4, Grade 0000000000
Blood Bilirubin Increased, Grade 4, Grade 1000000000
Blood Bilirubin Increased, Grade 4, Grade 2000000000
Blood Bilirubin Increased, Grade 4, Grade 3000000000
Creatinine Increased, Grade 0, Grade 1000162224
Creatinine Increased, Grade 0, Grade 2000000000
Creatinine Increased, Grade 0, Grade 3000000000
Creatinine Increased, Grade 0, Grade 4000000000
Creatinine Increased, Grade 1, Grade 0000000000
Creatinine Increased, Grade 1, Grade 2000001000
Creatinine Increased, Grade 1, Grade 3000000000
Creatinine Increased, Grade 1, Grade 4000000000
Creatinine Increased, Grade 2, Grade 0000000000
Creatinine Increased, Grade 2, Grade 1000000000
Creatinine Increased, Grade 2, Grade 3000000000
Creatinine Increased, Grade 2, Grade 4000000000
Creatinine Increased, Grade 3, Grade 0000000000
Creatinine Increased, Grade 3, Grade 1000000000
Creatinine Increased, Grade 3, Grade 2000000000
Creatinine Increased, Grade 3, Grade 4000000000
Creatinine Increased, Grade 4, Grade 0000000000
Creatinine Increased, Grade 4, Grade 1000000000
Creatinine Increased, Grade 4, Grade 2000000000
Creatinine Increased, Grade 4, Grade 3000000000
Hypokalemia , Grade 0, Grade 1000002040
Hypokalemia , Grade 0, Grade 2000000000
Hypokalemia , Grade 0, Grade 3000000000
Hypokalemia , Grade 0, Grade 4000000000
Hypokalemia , Grade 1, Grade 0000000000
Hypokalemia , Grade 1, Grade 2000000000
Hypokalemia , Grade 1, Grade 3000000000
Hypokalemia , Grade 1, Grade 4000000000
Hypokalemia , Grade 2, Grade 0000000000
Hypokalemia , Grade 2, Grade 1000000000
Hypokalemia , Grade 2, Grade 3000000000
Hypokalemia , Grade 2, Grade 4000000000
Hypokalemia , Grade 3, Grade 0000000000
Hypokalemia , Grade 3, Grade 1000000000
Hypokalemia , Grade 3, Grade 2000000000
Hypokalemia , Grade 3, Grade 4000000000
Hypokalemia , Grade 4, Grade 0000000000
Hypokalemia , Grade 4, Grade 1000000000
Hypokalemia , Grade 4, Grade 2000000000
Hypokalemia , Grade 4, Grade 3000000000
Hypokalemia , Missing, Grade 0————1————
Hypokalemia , Missing, Grade 1————0————
Hypokalemia , Missing, Grade 2————0————
Hypokalemia , Missing, Grade 3————0————
Hypokalemia , Missing, Grade 4————0————
Hyperkalemia , Grade 0, Grade 1010257461
Hyperkalemia , Grade 0, Grade 2000010010
Hyperkalemia , Grade 0, Grade 3000001100
Hyperkalemia , Grade 0, Grade 4000000000
Hyperkalemia , Grade 1, Grade 0000000000
Hyperkalemia , Grade 1, Grade 2000000000
Hyperkalemia , Grade 1, Grade 3000000000
Hyperkalemia , Grade 1, Grade 4000000000
Hyperkalemia , Grade 2, Grade 0000000000
Hyperkalemia , Grade 2, Grade 1000000000
Hyperkalemia , Grade 2, Grade 3000000000
Hyperkalemia , Grade 2, Grade 4000000000
Hyperkalemia , Grade 3, Grade 0000000000
Hyperkalemia , Grade 3, Grade 1000000000
Hyperkalemia , Grade 3, Grade 2000000000
Hyperkalemia , Grade 3, Grade 4000000000
Hyperkalemia , Grade 4, Grade 0000000000
Hyperkalemia , Grade 4, Grade 1000000000
Hyperkalemia , Grade 4, Grade 2000000000
Hyperkalemia , Grade 4, Grade 3000000000
Hyperkalemia , Missing, Grade 0————1————
Hyperkalemia , Missing, Grade 1————0————
Hyperkalemia , Missing, Grade 2————0————
Hyperkalemia , Missing, Grade 3————0————
Hyperkalemia , Missing, Grade 4————0————
Hyponatremia , Grade 0, Grade 1001337330
Hyponatremia , Grade 0, Grade 2000000000
Hyponatremia , Grade 0, Grade 3000011001
Hyponatremia , Grade 0, Grade 4000010000
Hyponatremia , Grade 1, Grade 0000000000
Hyponatremia , Grade 1, Grade 2000000000
Hyponatremia , Grade 1, Grade 3000000000
Hyponatremia , Grade 1, Grade 4000000000
Hyponatremia , Grade 2, Grade 0000000000
Hyponatremia , Grade 2, Grade 1000000000
Hyponatremia , Grade 2, Grade 3000000000
Hyponatremia , Grade 2, Grade 4000000000
Hyponatremia , Grade 3, Grade 0000000000
Hyponatremia , Grade 3, Grade 1000000000
Hyponatremia , Grade 3, Grade 2000000000
Hyponatremia , Grade 3, Grade 4000000000
Hyponatremia , Grade 4, Grade 0000000000
Hyponatremia , Grade 4, Grade 1000000000
Hyponatremia , Grade 4, Grade 2000000000
Hyponatremia , Grade 4, Grade 3000000000
Hypernatremia , Grade 0, Grade 1000000020
Hypernatremia , Grade 0, Grade 2000000010
Hypernatremia , Grade 0, Grade 3000000000
Hypernatremia , Grade 0, Grade 4000000000
Hypernatremia , Grade 1, Grade 0000000000
Hypernatremia , Grade 1, Grade 2000000000
Hypernatremia , Grade 1, Grade 3000000000
Hypernatremia , Grade 1, Grade 4000000000
Hypernatremia , Grade 2, Grade 0000000000
Hypernatremia , Grade 2, Grade 1000000000
Hypernatremia , Grade 2, Grade 3000000000
Hypernatremia , Grade 2, Grade 4000000000
Hypernatremia , Grade 3, Grade 0000000000
Hypernatremia , Grade 3, Grade 1000000000
Hypernatremia , Grade 3, Grade 2000000000
Hypernatremia , Grade 3, Grade 4000000000
Hypernatremia , Grade 4, Grade 0000000000
Hypernatremia , Grade 4, Grade 1000000000
Hypernatremia , Grade 4, Grade 2000000000
Hypernatremia , Grade 4, Grade 3000000000
Hypocalcemia , Grade 0, Grade 1000021130
Hypocalcemia , Grade 0, Grade 2000010000
Hypocalcemia , Grade 0, Grade 3000000000
Hypocalcemia , Grade 0, Grade 4000001000
Hypocalcemia , Grade 1, Grade 0000000000
Hypocalcemia , Grade 1, Grade 2000000000
Hypocalcemia , Grade 1, Grade 3000000000
Hypocalcemia , Grade 1, Grade 4000000000
Hypocalcemia , Grade 2, Grade 0000000100
Hypocalcemia , Grade 2, Grade 1000000000
Hypocalcemia , Grade 2, Grade 3000000000
Hypocalcemia , Grade 2, Grade 4000000000
Hypocalcemia , Grade 3, Grade 0000000000
Hypocalcemia , Grade 3, Grade 1000000000
Hypocalcemia , Grade 3, Grade 2000000000
Hypocalcemia , Grade 3, Grade 4000000000
Hypocalcemia , Grade 4, Grade 0000000000
Hypocalcemia , Grade 4, Grade 1000000000
Hypocalcemia , Grade 4, Grade 2000000000
Hypocalcemia , Grade 4, Grade 3000000000
Hypocalcemia , Missing, Grade 0————1————
Hypocalcemia , Missing, Grade 1————0————
Hypocalcemia , Missing, Grade 2————0————
Hypocalcemia , Missing, Grade 3————0————
Hypocalcemia , Missing, Grade 4————0————
Hypercalcemia , Grade 0, Grade 1000001000
Hypercalcemia , Grade 0, Grade 2000000000
Hypercalcemia , Grade 0, Grade 3000000000
Hypercalcemia , Grade 0, Grade 4000000000
Hypercalcemia , Grade 1, Grade 0000000010
Hypercalcemia , Grade 1, Grade 2000000000
Hypercalcemia , Grade 1, Grade 3000011000
Hypercalcemia , Grade 1, Grade 4000000000
Hypercalcemia , Grade 2, Grade 0000000000
Hypercalcemia , Grade 2, Grade 1000000000
Hypercalcemia , Grade 2, Grade 3000000000
Hypercalcemia , Grade 2, Grade 4000000000
Hypercalcemia , Grade 3, Grade 0000000000
Hypercalcemia , Grade 3, Grade 1000000000
Hypercalcemia , Grade 3, Grade 2000000000
Hypercalcemia , Grade 3, Grade 4000000000
Hypercalcemia , Grade 4, Grade 0000010000
Hypercalcemia , Grade 4, Grade 1000000000
Hypercalcemia , Grade 4, Grade 2000000000
Hypercalcemia , Grade 4, Grade 3000000000
Hypercalcemia , Missing, Grade 0————0————
Hypercalcemia , Missing, Grade 1————1————
Hypercalcemia , Missing, Grade 2————0————
Hypercalcemia , Missing, Grade 3————0————
Hypercalcemia , Missing, Grade 4————0————
Chronic Kidney Disease , Grade 0, Grade 1———010000
Chronic Kidney Disease , Grade 0, Grade 2———000100
Chronic Kidney Disease , Grade 0, Grade 3———000000
Chronic Kidney Disease , Grade 0, Grade 4———000000
Chronic Kidney Disease , Grade 1, Grade 0———000000
Chronic Kidney Disease , Grade 1, Grade 2———130001
Chronic Kidney Disease , Grade 1, Grade 3———000000
Chronic Kidney Disease , Grade 1, Grade 4———000000
Chronic Kidney Disease , Grade 2, Grade 0———000000
Chronic Kidney Disease , Grade 2, Grade 1———000000
Chronic Kidney Disease , Grade 2, Grade 3———000000
Chronic Kidney Disease , Grade 2, Grade 4———000000
Chronic Kidney Disease , Grade 3, Grade 0———000000
Chronic Kidney Disease , Grade 3, Grade 1———000000
Chronic Kidney Disease , Grade 3, Grade 2———000000
Chronic Kidney Disease , Grade 3, Grade 4———000000
Chronic Kidney Disease , Grade 4, Grade 0———000000
Chronic Kidney Disease , Grade 4, Grade 1———000000
Chronic Kidney Disease , Grade 4, Grade 2———000000
Chronic Kidney Disease , Grade 4, Grade 3———000000
Chronic Kidney Disease , Missing, Grade 0————01—1—
Chronic Kidney Disease , Missing, Grade 1————11—0—
Chronic Kidney Disease , Missing, Grade 2————00—1—
Chronic Kidney Disease , Missing, Grade 3————00—0—
Chronic Kidney Disease , Missing, Grade 4————01—0—
PrimaryPart 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Direct Bilirubin (umol/L), To Low————0————
Direct Bilirubin (umol/L), To Normal or No Change————0————
Direct Bilirubin (umol/L), To High————1————
Lactate Dehydrogenase (IU/L), To Low————000——
Lactate Dehydrogenase (IU/L), To Normal or No Change————000——
Lactate Dehydrogenase (IU/L), To High————121——
Protein (g/L), To Low000267131
Protein (g/L), To Normal or No Change112518159215
Protein (g/L), To High000003441
Triiodothyronine, Free (pmol/L), To Low000356221
Triiodothyronine, Free (pmol/L), To Normal or No Change110412168215
Triiodothyronine, Free (pmol/L), To High001021101
Thyroxine, Free (pmol/L), To Low000001001
Thyroxine, Free (pmol/L), To Normal or No Change1116192110225
Thyroxine, Free (pmol/L), To High000102111
Troponin I (ug/L), To Low0—0000000
Troponin I (ug/L), To Normal or No Change1—13610182
Troponin I (ug/L), To High0—0120101
Troponin T (ug/L), To Low————00000
Troponin T (ug/L), To Normal or No Change————888102
Troponin T (ug/L), To High————30130
Thyrotropin (mU/L), To Low000001110
Thyrotropin (mU/L), To Normal or No Change1115182110207
Thyrotropin (mU/L), To High000212020
Urea (mmol/L), To Low000013200
Urea (mmol/L), To Normal or No Change101312117152
Urea (mmol/L), To High011366363
PrimaryPart 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Anemia , Grade 0, Grade 1100381261
Anemia , Grade 0, Grade 2000003000
Anemia , Grade 0, Grade 3000010000
Anemia , Grade 0, Grade 4000000000
Anemia , Grade 1, Grade 0000000000
Anemia , Grade 1, Grade 2001145232
Anemia , Grade 1, Grade 3000101110
Anemia , Grade 1, Grade 4000000000
Anemia , Grade 2, Grade 0000000000
Anemia , Grade 2, Grade 1000000000
Anemia , Grade 2, Grade 3000021010
Anemia , Grade 2, Grade 4000000000
Anemia , Grade 3, Grade 0000000000
Anemia , Grade 3, Grade 1000000000
Anemia , Grade 3, Grade 2000000000
Anemia , Grade 3, Grade 4000000000
Anemia , Grade 4, Grade 0000000000
Anemia , Grade 4, Grade 1000000000
Anemia , Grade 4, Grade 2000000000
Anemia , Grade 4, Grade 3000000000
Hemoglobin Increased, Grade 0, Grade 1000000001
Hemoglobin Increased, Grade 0, Grade 2000000000
Hemoglobin Increased, Grade 0, Grade 3000000000
Hemoglobin Increased, Grade 0, Grade 4000000000
Hemoglobin Increased, Grade 1, Grade 0000000000
Hemoglobin Increased, Grade 1, Grade 2000000000
Hemoglobin Increased, Grade 1, Grade 3000000000
Hemoglobin Increased, Grade 1, Grade 4000000000
Hemoglobin Increased, Grade 2, Grade 0000000000
Hemoglobin Increased, Grade 2, Grade 1000000000
Hemoglobin Increased, Grade 2, Grade 3000000000
Hemoglobin Increased, Grade 2, Grade 4000000000
Hemoglobin Increased, Grade 3, Grade 0000000000
Hemoglobin Increased, Grade 3, Grade 1000000000
Hemoglobin Increased, Grade 3, Grade 2000000000
Hemoglobin Increased, Grade 3, Grade 4000000000
Hemoglobin Increased, Grade 4, Grade 0000000000
Hemoglobin Increased, Grade 4, Grade 1000000000
Hemoglobin Increased, Grade 4, Grade 2000000000
Hemoglobin Increased, Grade 4, Grade 3000000000
Lymphocyte Count Decreased, Grade 0, Grade 1100155263
Lymphocyte Count Decreased, Grade 0, Grade 2000133220
Lymphocyte Count Decreased, Grade 0, Grade 3000100210
Lymphocyte Count Decreased, Grade 0, Grade 4000000000
Lymphocyte Count Decreased, Grade 1, Grade 0000000000
Lymphocyte Count Decreased, Grade 1, Grade 2001052111
Lymphocyte Count Decreased, Grade 1, Grade 3000021010
Lymphocyte Count Decreased, Grade 1, Grade 4000000000
Lymphocyte Count Decreased, Grade 2, Grade 0000000010
Lymphocyte Count Decreased, Grade 2, Grade 1000000000
Lymphocyte Count Decreased, Grade 2, Grade 3000001030
Lymphocyte Count Decreased, Grade 2, Grade 4000000000
Lymphocyte Count Decreased, Grade 3, Grade 0000000000
Lymphocyte Count Decreased, Grade 3, Grade 1000000000
Lymphocyte Count Decreased, Grade 3, Grade 2000000000
Lymphocyte Count Decreased, Grade 3, Grade 4000000000
Lymphocyte Count Decreased, Grade 4, Grade 0000000000
Lymphocyte Count Decreased, Grade 4, Grade 1000000000
Lymphocyte Count Decreased, Grade 4, Grade 2000000000
Lymphocyte Count Decreased, Grade 4, Grade 3000000000
Lymphocyte Count Decreased, Missing, Grade 0————0————
Lymphocyte Count Decreased, Missing, Grade 1————0————
Lymphocyte Count Decreased, Missing, Grade 2————0————
Lymphocyte Count Decreased, Missing, Grade 3————1————
Lymphocyte Count Decreased, Missing, Grade 4————0————
Lymphocyte Count Increased, Grade 0, Grade 1000000000
Lymphocyte Count Increased, Grade 0, Grade 2000020110
Lymphocyte Count Increased, Grade 0, Grade 3000001000
Lymphocyte Count Increased, Grade 0, Grade 4000000000
Lymphocyte Count Increased, Grade 1, Grade 0000000000
Lymphocyte Count Increased, Grade 1, Grade 2000000000
Lymphocyte Count Increased, Grade 1, Grade 3000000000
Lymphocyte Count Increased, Grade 1, Grade 4000000000
Lymphocyte Count Increased, Grade 2, Grade 0000000000
Lymphocyte Count Increased, Grade 2, Grade 1000000000
Lymphocyte Count Increased, Grade 2, Grade 3000000000
Lymphocyte Count Increased, Grade 2, Grade 4000000000
Lymphocyte Count Increased, Grade 3, Grade 0000000000
Lymphocyte Count Increased, Grade 3, Grade 1000000000
Lymphocyte Count Increased, Grade 3, Grade 2000000000
Lymphocyte Count Increased, Grade 3, Grade 4000000000
Lymphocyte Count Increased, Grade 4, Grade 0000000000
Lymphocyte Count Increased, Grade 4, Grade 1000000000
Lymphocyte Count Increased, Grade 4, Grade 2000000000
Lymphocyte Count Increased, Grade 4, Grade 3000000000
Lymphocyte Count Increased, Missing, Grade 0————1————
Lymphocyte Count Increased, Missing, Grade 1————0————
Lymphocyte Count Increased, Missing, Grade 2————0————
Lymphocyte Count Increased, Missing, Grade 3————0————
Lymphocyte Count Increased, Missing, Grade 4————0————
Neutrophil Count Decreased, Grade 0, Grade 1000011201
Neutrophil Count Decreased, Grade 0, Grade 2000012000
Neutrophil Count Decreased, Grade 0, Grade 3000000010
Neutrophil Count Decreased, Grade 0, Grade 4000000001
Neutrophil Count Decreased, Grade 1, Grade 0000000000
Neutrophil Count Decreased, Grade 1, Grade 2000010000
Neutrophil Count Decreased, Grade 1, Grade 3000000000
Neutrophil Count Decreased, Grade 1, Grade 4000000000
Neutrophil Count Decreased, Grade 2, Grade 0000000000
Neutrophil Count Decreased, Grade 2, Grade 1000000000
Neutrophil Count Decreased, Grade 2, Grade 3000000000
Neutrophil Count Decreased, Grade 2, Grade 4000000000
Neutrophil Count Decreased, Grade 3, Grade 0000000000
Neutrophil Count Decreased, Grade 3, Grade 1000000000
Neutrophil Count Decreased, Grade 3, Grade 2000000000
Neutrophil Count Decreased, Grade 3, Grade 4000000000
Neutrophil Count Decreased, Grade 4, Grade 0000000000
Neutrophil Count Decreased, Grade 4, Grade 1000000000
Neutrophil Count Decreased, Grade 4, Grade 2000000000
Neutrophil Count Decreased, Grade 4, Grade 3000000000
Neutrophil Count Decreased, Missing, Grade 0————1————
Neutrophil Count Decreased, Missing, Grade 1————0————
Neutrophil Count Decreased, Missing, Grade 2————0————
Neutrophil Count Decreased, Missing, Grade 3————0————
Neutrophil Count Decreased, Missing, Grade 4————0————
Platelet Count Decreased, Grade 0, Grade 1000000010
Platelet Count Decreased, Grade 0, Grade 2000000000
Platelet Count Decreased, Grade 0, Grade 3000000000
Platelet Count Decreased, Grade 0, Grade 4000001000
Platelet Count Decreased, Grade 1, Grade 0010001000
Platelet Count Decreased, Grade 1, Grade 2000000000
Platelet Count Decreased, Grade 1, Grade 3000000000
Platelet Count Decreased, Grade 1, Grade 4000000000
Platelet Count Decreased, Grade 2, Grade 0000000000
Platelet Count Decreased, Grade 2, Grade 1000000000
Platelet Count Decreased, Grade 2, Grade 3000000000
Platelet Count Decreased, Grade 2, Grade 4000000000
Platelet Count Decreased, Grade 3, Grade 0000000000
Platelet Count Decreased, Grade 3, Grade 1000000000
Platelet Count Decreased, Grade 3, Grade 2000000000
Platelet Count Decreased, Grade 3, Grade 4000000000
Platelet Count Decreased, Grade 4, Grade 0000000000
Platelet Count Decreased, Grade 4, Grade 1000000000
Platelet Count Decreased, Grade 4, Grade 2000000000
Platelet Count Decreased, Grade 4, Grade 3000000000
White Blood Cell Decreased, Grade 0, Grade 1011134112
White Blood Cell Decreased, Grade 0, Grade 2000000020
White Blood Cell Decreased, Grade 0, Grade 3000000000
White Blood Cell Decreased, Grade 0, Grade 4000000000
White Blood Cell Decreased, Grade 1, Grade 0000000100
White Blood Cell Decreased, Grade 1, Grade 2000001000
White Blood Cell Decreased, Grade 1, Grade 3000000000
White Blood Cell Decreased, Grade 1, Grade 4000000000
White Blood Cell Decreased, Grade 2, Grade 0000000000
White Blood Cell Decreased, Grade 2, Grade 1000000000
White Blood Cell Decreased, Grade 2, Grade 3000000000
White Blood Cell Decreased, Grade 2, Grade 4000000000
White Blood Cell Decreased, Grade 3, Grade 0000000000
White Blood Cell Decreased, Grade 3, Grade 1000000000
White Blood Cell Decreased, Grade 3, Grade 2000000000
White Blood Cell Decreased, Grade 3, Grade 4000000000
White Blood Cell Decreased, Grade 4, Grade 0000000000
White Blood Cell Decreased, Grade 4, Grade 1000000000
White Blood Cell Decreased, Grade 4, Grade 2000000000
White Blood Cell Decreased, Grade 4, Grade 3000000000
Leukocytosis , Grade 0, Grade 1000000000
Leukocytosis , Grade 0, Grade 2000000000
Leukocytosis , Grade 0, Grade 3000000000
Leukocytosis , Grade 0, Grade 4000000000
Leukocytosis , Grade 1, Grade 0000000000
Leukocytosis , Grade 1, Grade 2000000000
Leukocytosis , Grade 1, Grade 3000000000
Leukocytosis , Grade 1, Grade 4000000000
Leukocytosis , Grade 2, Grade 0000000000
Leukocytosis , Grade 2, Grade 1000000000
Leukocytosis , Grade 2, Grade 3000000000
Leukocytosis , Grade 2, Grade 4000000000
Leukocytosis , Grade 3, Grade 0000000000
Leukocytosis , Grade 3, Grade 1000000000
Leukocytosis , Grade 3, Grade 2000000000
Leukocytosis , Grade 3, Grade 4000000000
Leukocytosis , Grade 4, Grade 0000000000
Leukocytosis , Grade 4, Grade 1000000000
Leukocytosis , Grade 4, Grade 2000000000
Leukocytosis , Grade 4, Grade 3000000000
PrimaryPart 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Basophils, To Low000000000
Basophils, To Normal or No Change1126242411227
Basophils, To High000100100
Eosinophils, To Low010032221
Eosinophils, To Normal or No Change1027202010216
Eosinophils, To High000034150
Hematocrit, To Low0012107262
Hematocrit, To Normal or No Change1115141813215
Hematocrit, To High000000001
Lymphocytes, To Low————211——
Lymphocytes, To Normal or No Change————000——
Lymphocytes, To High————000——
Erythrocytes, Mean Corpuscular Volume, To Low——————1——
Erythrocytes, Mean Corpuscular Volume, To Normal or No Change——————0——
Erythrocytes, Mean Corpuscular Volume, To High——————0——
Monocytes, To Low000011000
Monocytes, To Normal or No Change0115182111216
Monocytes, To High101253361
Neutrophils, To Low————000——
Neutrophils, To Normal or No Change————000——
Neutrophils, To High————111——
Erythrocytes, To Low001077033
Erythrocytes, To Normal or No Change1117171814243
Erythrocytes, To High000000001
PrimaryPart 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Glucose, No Change/Decreased1127232212257
Glucose, any increase000013220
Ketones, No Change/Decreased0016192110155
Ketones, any increase1111444122
Occult Blood, No Change/Decreased111517188157
Occult Blood, any increase0012676120
PrimaryPart 1A: Number of Participants With Dose Modifications of Feladilimab

Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Dose Modifications of Feladilimab
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Dose Delays000121231
Dose Escalations000231100
infusion interruptions000000000
PrimaryPart 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Any AEs5555810041543636132214
Any SAEs3232340252141331701
PrimaryPart 2A: Number of Participants With Dose Limiting Toxicity (DLT)

DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)000001000000213——
PrimaryPart 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Hypoglycemia , Grade 0, Grade 110001100210051100
Hypoglycemia , Grade 0, Grade 200000000000011100
Hypoglycemia , Grade 0, Grade 300000000000000000
Hypoglycemia , Grade 0, Grade 400000000000000000
Hypoglycemia , Grade 1, Grade 000000000000010000
Hypoglycemia , Grade 1, Grade 200000000000000000
Hypoglycemia , Grade 1, Grade 300000000000000000
Hypoglycemia , Grade 1, Grade 400000000000000000
Hypoglycemia , Grade 2, Grade 000000000000000000
Hypoglycemia , Grade 2, Grade 100000000000000000
Hypoglycemia , Grade 2, Grade 300000000000000000
Hypoglycemia , Grade 2, Grade 400000000000000000
Hypoglycemia , Grade 3, Grade 000000000000000000
Hypoglycemia , Grade 3, Grade 100000000000000000
Hypoglycemia , Grade 3, Grade 200000000000000000
Hypoglycemia , Grade 3, Grade 400000000000000000
Hypoglycemia , Grade 4, Grade 000000000000000000
Hypoglycemia , Grade 4, Grade 100000000000000000
Hypoglycemia , Grade 4, Grade 200000000000000000
Hypoglycemia , Grade 4, Grade 300000000000000000
Hyperglycemia , Grade 0, Grade 1032534004001125903
Hyperglycemia , Grade 0, Grade 200010200210142100
Hyperglycemia , Grade 0, Grade 300000000000010100
Hyperglycemia , Grade 0, Grade 400000100000000000
Hyperglycemia , Grade 1, Grade 000000000000010000
Hyperglycemia , Grade 1, Grade 211001000100022100
Hyperglycemia , Grade 1, Grade 300000000100001010
Hyperglycemia , Grade 1, Grade 400100000000000000
Hyperglycemia , Grade 2, Grade 000000000000020000
Hyperglycemia , Grade 2, Grade 100000000000010100
Hyperglycemia , Grade 2, Grade 300000000000000100
Hyperglycemia , Grade 2, Grade 400000000000000100
Hyperglycemia , Grade 3, Grade 000000000000000000
Hyperglycemia , Grade 3, Grade 100000000000000000
Hyperglycemia , Grade 3, Grade 200000000000000000
Hyperglycemia , Grade 3, Grade 400000000000000000
Hyperglycemia , Grade 4, Grade 000000000000000000
Hyperglycemia , Grade 4, Grade 100000000000000000
Hyperglycemia , Grade 4, Grade 200000000000000000
Hyperglycemia , Grade 4, Grade 300000000000000000
Hypoalbuminemia , Grade 0, Grade 121113300200155600
Hypoalbuminemia , Grade 0, Grade 201010000101051300
Hypoalbuminemia , Grade 0, Grade 300000000000010000
Hypoalbuminemia , Grade 0, Grade 400000000000000000
Hypoalbuminemia , Grade 1, Grade 000000000000000000
Hypoalbuminemia , Grade 1, Grade 201120000000043000
Hypoalbuminemia , Grade 1, Grade 300000000000100000
Hypoalbuminemia , Grade 1, Grade 400000000000000000
Hypoalbuminemia , Grade 2, Grade 000000000000000000
Hypoalbuminemia , Grade 2, Grade 100000000000000000
Hypoalbuminemia , Grade 2, Grade 300000000000000000
Hypoalbuminemia , Grade 2, Grade 400000000000000000
Hypoalbuminemia , Grade 3, Grade 000000000000000000
Hypoalbuminemia , Grade 3, Grade 100000000000000000
Hypoalbuminemia , Grade 3, Grade 200000000000000000
Hypoalbuminemia , Grade 3, Grade 400000000000000000
Hypoalbuminemia , Grade 4, Grade 000000000000000000
Hypoalbuminemia , Grade 4, Grade 100000000000000000
Hypoalbuminemia , Grade 4, Grade 200000000000000000
Hypoalbuminemia , Grade 4, Grade 300000000000000000
Hypoalbuminemia , Missing, Grade 0————————————0————
Hypoalbuminemia , Missing, Grade 1————————————1————
Hypoalbuminemia , Missing, Grade 2————————————0————
Hypoalbuminemia , Missing, Grade 3————————————0————
Hypoalbuminemia , Missing, Grade 4————————————0————
AP Increased, Grade 0, Grade 110233210601173601
AP Increased, Grade 0, Grade 200010000000000000
AP Increased, Grade 0, Grade 300000000000000100
AP Increased, Grade 0, Grade 400000000000000000
AP Increased, Grade 1, Grade 000000000001000000
AP Increased, Grade 1, Grade 201010200000001001
AP Increased, Grade 1, Grade 300100000010000000
AP Increased, Grade 1, Grade 400000000000000000
AP Increased, Grade 2, Grade 000000000000000000
AP Increased, Grade 2, Grade 100000000000000000
AP Increased, Grade 2, Grade 300000100000000000
AP Increased, Grade 2, Grade 400000000000000000
AP Increased, Grade 3, Grade 000000000000000000
AP Increased, Grade 3, Grade 100000000000000000
AP Increased, Grade 3, Grade 200000000000010000
AP Increased, Grade 3, Grade 400000000000000000
AP Increased, Grade 4, Grade 000000000000000000
AP Increased, Grade 4, Grade 100000000000000000
AP Increased, Grade 4, Grade 200000000000000000
AP Increased, Grade 4, Grade 300000000000000000
ALT Increased, Grade 0, Grade 1001211001002105700
ALT Increased, Grade 0, Grade 200121100000001100
ALT Increased, Grade 0, Grade 300101000000000000
ALT Increased, Grade 0, Grade 400000000000000100
ALT Increased, Grade 1, Grade 000000000000010100
ALT Increased, Grade 1, Grade 200000000100000000
ALT Increased, Grade 1, Grade 300000000000100000
ALT Increased, Grade 1, Grade 400000000000000000
ALT Increased, Grade 2, Grade 000000000000000000
ALT Increased, Grade 2, Grade 100000000000010000
ALT Increased, Grade 2, Grade 300000000000000000
ALT Increased, Grade 2, Grade 400000000000000000
ALT Increased, Grade 3, Grade 000000000000000000
ALT Increased, Grade 3, Grade 100000000000000000
ALT Increased, Grade 3, Grade 200000000000000000
ALT Increased, Grade 3, Grade 400000000000000000
ALT Increased, Grade 4, Grade 000000000000000000
ALT Increased, Grade 4, Grade 100000000000000000
ALT Increased, Grade 4, Grade 200000000000000000
ALT Increased, Grade 4, Grade 300000000000000000
AST Increased, Grade 0, Grade 101352600110092502
AST Increased, Grade 0, Grade 200001100000001100
AST Increased, Grade 0, Grade 300000000000000000
AST Increased, Grade 0, Grade 400000000000000100
AST Increased, Grade 1, Grade 000000000000010100
AST Increased, Grade 1, Grade 200000000000120000
AST Increased, Grade 1, Grade 300100000000000000
AST Increased, Grade 1, Grade 400000000000000000
AST Increased, Grade 2, Grade 000000000000000000
AST Increased, Grade 2, Grade 100000000000000000
AST Increased, Grade 2, Grade 300000000000000000
AST Increased, Grade 2, Grade 400000000000000000
AST Increased, Grade 3, Grade 000000000000000000
AST Increased, Grade 3, Grade 100000000000000000
AST Increased, Grade 3, Grade 200000000000000000
AST Increased, Grade 3, Grade 400000000000000000
AST Increased, Grade 4, Grade 000000000000000000
AST Increased, Grade 4, Grade 100000000000000000
AST Increased, Grade 4, Grade 200000000000000000
AST Increased, Grade 4, Grade 300000000000000000
Blood Bilirubin Increased, Grade 0, Grade 100101000110121200
Blood Bilirubin Increased, Grade 0, Grade 200000000000010000
Blood Bilirubin Increased, Grade 0, Grade 300010000000000100
Blood Bilirubin Increased, Grade 0, Grade 400000000000000000
Blood Bilirubin Increased, Grade 1, Grade 000000000000000000
Blood Bilirubin Increased, Grade 1, Grade 200000000000000000
Blood Bilirubin Increased, Grade 1, Grade 300000000000010000
Blood Bilirubin Increased, Grade 1, Grade 400000000000000000
Blood Bilirubin Increased, Grade 2, Grade 000000000000000000
Blood Bilirubin Increased, Grade 2, Grade 100000000000000000
Blood Bilirubin Increased, Grade 2, Grade 300000000000000000
Blood Bilirubin Increased, Grade 2, Grade 400000000000000000
Blood Bilirubin Increased, Grade 3, Grade 000000000000000000
Blood Bilirubin Increased, Grade 3, Grade 100000000000000000
Blood Bilirubin Increased, Grade 3, Grade 200000000000000000
Blood Bilirubin Increased, Grade 3, Grade 400000000000000000
Blood Bilirubin Increased, Grade 4, Grade 000000000000000000
Blood Bilirubin Increased, Grade 4, Grade 100000000000000000
Blood Bilirubin Increased, Grade 4, Grade 200000000000000000
Blood Bilirubin Increased, Grade 4, Grade 300000000000000000
Creatinine Increased, Grade 0, Grade 100020100200122200
Creatinine Increased, Grade 0, Grade 200001000000120100
Creatinine Increased, Grade 0, Grade 300000000000000000
Creatinine Increased, Grade 0, Grade 400000000000010000
Creatinine Increased, Grade 1, Grade 000001000000000000
Creatinine Increased, Grade 1, Grade 200000000000000000
Creatinine Increased, Grade 1, Grade 300000000000000000
Creatinine Increased, Grade 1, Grade 400000000000000000
Creatinine Increased, Grade 2, Grade 000000000000000000
Creatinine Increased, Grade 2, Grade 100000000000000000
Creatinine Increased, Grade 2, Grade 300000000000000000
Creatinine Increased, Grade 2, Grade 400000000000000000
Creatinine Increased, Grade 3, Grade 000000000000000000
Creatinine Increased, Grade 3, Grade 100000000000000000
Creatinine Increased, Grade 3, Grade 200000000000000000
Creatinine Increased, Grade 3, Grade 400000000000000000
Creatinine Increased, Grade 4, Grade 000000000000000000
Creatinine Increased, Grade 4, Grade 100000000000000000
Creatinine Increased, Grade 4, Grade 200000000000000000
Creatinine Increased, Grade 4, Grade 300000000000000000
Creatinine Increased, Missing, Grade 0————————————1—0——
Creatinine Increased, Missing, Grade 1————————————0—0——
Creatinine Increased, Missing, Grade 2————————————0—0——
Creatinine Increased, Missing, Grade 3————————————0—0——
Creatinine Increased, Missing, Grade 4————————————0—1——
Hypokalemia , Grade 0, Grade 111011200100245300
Hypokalemia , Grade 0, Grade 200000000000000000
Hypokalemia , Grade 0, Grade 300000000000011300
Hypokalemia , Grade 0, Grade 400000000000000000
Hypokalemia , Grade 1, Grade 000000000000000100
Hypokalemia , Grade 1, Grade 200000000000000000
Hypokalemia , Grade 1, Grade 300000000100000100
Hypokalemia , Grade 1, Grade 400000000000000000
Hypokalemia , Grade 2, Grade 000000000000000000
Hypokalemia , Grade 2, Grade 100000000000000000
Hypokalemia , Grade 2, Grade 300000000000000000
Hypokalemia , Grade 2, Grade 400000000000000000
Hypokalemia , Grade 3, Grade 000000000000000000
Hypokalemia , Grade 3, Grade 100000000000000000
Hypokalemia , Grade 3, Grade 200000000000000000
Hypokalemia , Grade 3, Grade 400000000000000000
Hypokalemia , Grade 4, Grade 000000000000000000
Hypokalemia , Grade 4, Grade 100000000000000000
Hypokalemia , Grade 4, Grade 200000000000000000
Hypokalemia , Grade 4, Grade 300000000000000000
Hyperkalemia , Grade 0, Grade 101122101200064300
Hyperkalemia , Grade 0, Grade 200100100000020000
Hyperkalemia , Grade 0, Grade 300000000000000000
Hyperkalemia , Grade 0, Grade 400000000100000000
Hyperkalemia , Grade 1, Grade 000000100000001000
Hyperkalemia , Grade 1, Grade 210000000000000000
Hyperkalemia , Grade 1, Grade 300000000000000000
Hyperkalemia , Grade 1, Grade 400000000000000000
Hyperkalemia , Grade 2, Grade 000000000000000000
Hyperkalemia , Grade 2, Grade 100000000000000000
Hyperkalemia , Grade 2, Grade 300000000000000000
Hyperkalemia , Grade 2, Grade 400000000000000000
Hyperkalemia , Grade 3, Grade 000000000000000000
Hyperkalemia , Grade 3, Grade 100000000000000000
Hyperkalemia , Grade 3, Grade 200000000000000000
Hyperkalemia , Grade 3, Grade 400000000000000000
Hyperkalemia , Grade 4, Grade 000000000000000000
Hyperkalemia , Grade 4, Grade 100000000000000000
Hyperkalemia , Grade 4, Grade 200000000000000000
Hyperkalemia , Grade 4, Grade 300000000000000000
Hyponatremia , Grade 0, Grade 1102256021202891201
Hyponatremia , Grade 0, Grade 200000000000000000
Hyponatremia , Grade 0, Grade 300000000000051100
Hyponatremia , Grade 0, Grade 400000000000000000
Hyponatremia , Grade 1, Grade 000000000000000000
Hyponatremia , Grade 1, Grade 200000000000000000
Hyponatremia , Grade 1, Grade 310000000100010100
Hyponatremia , Grade 1, Grade 400000000000000000
Hyponatremia , Grade 2, Grade 000000000000000000
Hyponatremia , Grade 2, Grade 100000000000000000
Hyponatremia , Grade 2, Grade 300000000000000000
Hyponatremia , Grade 2, Grade 400000000000000000
Hyponatremia , Grade 3, Grade 000000000000000000
Hyponatremia , Grade 3, Grade 100000000000000000
Hyponatremia , Grade 3, Grade 200000000000000000
Hyponatremia , Grade 3, Grade 400000000000000000
Hyponatremia , Grade 4, Grade 000000000000000000
Hyponatremia , Grade 4, Grade 100000000000000000
Hyponatremia , Grade 4, Grade 200000000000000000
Hyponatremia , Grade 4, Grade 300000000000000000
Hypernatremia , Grade 0, Grade 100000000000051000
Hypernatremia , Grade 0, Grade 210000000000000000
Hypernatremia , Grade 0, Grade 300000000000000000
Hypernatremia , Grade 0, Grade 400000000000100100
Hypernatremia , Grade 1, Grade 000010100000000000
Hypernatremia , Grade 1, Grade 200000000000000000
Hypernatremia , Grade 1, Grade 300000000000000000
Hypernatremia , Grade 1, Grade 400000000000000000
Hypernatremia , Grade 2, Grade 000000000000000000
Hypernatremia , Grade 2, Grade 100000000000000000
Hypernatremia , Grade 2, Grade 300000000000000000
Hypernatremia , Grade 2, Grade 400000000000000000
Hypernatremia , Grade 3, Grade 000000000000000000
Hypernatremia , Grade 3, Grade 100000000000000000
Hypernatremia , Grade 3, Grade 200000000000000000
Hypernatremia , Grade 3, Grade 400000000000000000
Hypernatremia , Grade 4, Grade 000000000000000000
Hypernatremia , Grade 4, Grade 100000000000000000
Hypernatremia , Grade 4, Grade 200000000000000000
Hypernatremia , Grade 4, Grade 300000000000000000
Hypocalcemia , Grade 0, Grade 110111200100075100
Hypocalcemia , Grade 0, Grade 200000000000011100
Hypocalcemia , Grade 0, Grade 300000000100000000
Hypocalcemia , Grade 0, Grade 400000000000000100
Hypocalcemia , Grade 1, Grade 000000100100000000
Hypocalcemia , Grade 1, Grade 200000000000000000
Hypocalcemia , Grade 1, Grade 300000000000000000
Hypocalcemia , Grade 1, Grade 400000000000000000
Hypocalcemia , Grade 2, Grade 000000000000000000
Hypocalcemia , Grade 2, Grade 100000000000000000
Hypocalcemia , Grade 2, Grade 300000000000000000
Hypocalcemia , Grade 2, Grade 400000000000000000
Hypocalcemia , Grade 3, Grade 000000000000000000
Hypocalcemia , Grade 3, Grade 100000000000000000
Hypocalcemia , Grade 3, Grade 200000000000000000
Hypocalcemia , Grade 3, Grade 400000000000000000
Hypocalcemia , Grade 4, Grade 000000000000000000
Hypocalcemia , Grade 4, Grade 100000000000000000
Hypocalcemia , Grade 4, Grade 200000000000000000
Hypocalcemia , Grade 4, Grade 300000000000000000
Hypocalcemia , Missing, Grade 0————————————1————
Hypocalcemia , Missing, Grade 1————————————0————
Hypocalcemia , Missing, Grade 2————————————0————
Hypocalcemia , Missing, Grade 3————————————0————
Hypocalcemia , Missing, Grade 4————————————0————
Hypercalcemia , Grade 0, Grade 110110102100042100
Hypercalcemia , Grade 0, Grade 200000000000010000
Hypercalcemia , Grade 0, Grade 300000000000001000
Hypercalcemia , Grade 0, Grade 400010000000000000
Hypercalcemia , Grade 1, Grade 000000000000102000
Hypercalcemia , Grade 1, Grade 200000000000010000
Hypercalcemia , Grade 1, Grade 300000000000100000
Hypercalcemia , Grade 1, Grade 402000000000000000
Hypercalcemia , Grade 2, Grade 000000000000000000
Hypercalcemia , Grade 2, Grade 100000000000000000
Hypercalcemia , Grade 2, Grade 300000000101010401
Hypercalcemia , Grade 2, Grade 400000000000000000
Hypercalcemia , Grade 3, Grade 000000000000000000
Hypercalcemia , Grade 3, Grade 100000000000000000
Hypercalcemia , Grade 3, Grade 200000000000000000
Hypercalcemia , Grade 3, Grade 400000000000000000
Hypercalcemia , Grade 4, Grade 000000000000000000
Hypercalcemia , Grade 4, Grade 100000000000000000
Hypercalcemia , Grade 4, Grade 200000000000000000
Hypercalcemia , Grade 4, Grade 300000000000000000
Hypercalcemia , Missing, Grade 0————————————1————
Hypercalcemia , Missing, Grade 1————————————0————
Hypercalcemia , Missing, Grade 2————————————0————
Hypercalcemia , Missing, Grade 3————————————0————
Hypercalcemia , Missing, Grade 4————————————0————
Chronic Kidney Disease , Grade 0, Grade 1—00011——0——0000——
Chronic Kidney Disease , Grade 0, Grade 2—00000——0——0010——
Chronic Kidney Disease , Grade 0, Grade 3—00000——0——0000——
Chronic Kidney Disease , Grade 0, Grade 4—00000——0——0000——
Chronic Kidney Disease , Grade 1, Grade 0—00000——0——0000——
Chronic Kidney Disease , Grade 1, Grade 2—00100——1——0000——
Chronic Kidney Disease , Grade 1, Grade 3—00000——0——0000——
Chronic Kidney Disease , Grade 1, Grade 4—00000——0——0000——
Chronic Kidney Disease , Grade 2, Grade 0—00000——0——0000——
Chronic Kidney Disease , Grade 2, Grade 1—00000——0——0000——
Chronic Kidney Disease , Grade 2, Grade 3—00000——0——0000——
Chronic Kidney Disease , Grade 2, Grade 4—00000——0——0000——
Chronic Kidney Disease , Grade 3, Grade 0—00000——0——0000——
Chronic Kidney Disease , Grade 3, Grade 1—00000——0——0000——
Chronic Kidney Disease , Grade 3, Grade 2—00000——0——0000——
Chronic Kidney Disease , Grade 3, Grade 4—00000——0——0000——
Chronic Kidney Disease , Grade 4, Grade 0—00000——0——0000——
Chronic Kidney Disease , Grade 4, Grade 1—00000——0——0000——
Chronic Kidney Disease , Grade 4, Grade 2—00000——0——0000——
Chronic Kidney Disease , Grade 4, Grade 3—00000——0——0000——
Chronic Kidney Disease , Missing, Grade 0———000——0——1100——
Chronic Kidney Disease , Missing, Grade 1———101——1——0312——
Chronic Kidney Disease , Missing, Grade 2———010——0——1500——
Chronic Kidney Disease , Missing, Grade 3———000——0——1000——
Chronic Kidney Disease , Missing, Grade 4———001——0——0010——
PrimaryPart 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Lactate Dehydrogenase (IU/L), To Low————————000—000—0
Lactate Dehydrogenase (IU/L), To Normal or No Change————————221—113—1
Lactate Dehydrogenase (IU/L), To High————————000—002—2
Protein (g/L), To Low2223100032001661202
Protein (g/L), To Normal or No Change33338100412233186911
Protein (g/L), To High00022110000231002
Triiodothyronine, Free (pmol/L), To Low00014100200154200
Triiodothyronine, Free (pmol/L), To Normal or No Change25364612102332671813
Triiodothyronine, Free (pmol/L), To High10122300100103001
Thyroxine, Free (pmol/L), To Low00021100000000500
Thyroxine, Free (pmol/L), To Normal or No Change353686121322331121414
Thyroxine, Free (pmol/L), To High10110400101101200
Troponin I (ug/L), To Low000000—0000000300
Troponin I (ug/L), To Normal or No Change112343—13214119912
Troponin I (ug/L), To High100111—0001010601
Troponin T (ug/L), To Low000000——0—0—000—0
Troponin T (ug/L), To Normal or No Change211223——8—1—1222—3
Troponin T (ug/L), To High000100——2—0—110—0
Thyrotropin (mU/L), To Low10210100200021000
Thyrotropin (mU/L), To Normal or No Change25256911812223111713
Thyrotropin (mU/L), To High10133001411261301
Urea (mmol/L), To Low10002201001212000
Urea (mmol/L), To Normal or No Change3324461292111731212
Urea (mmol/L), To High11334301321368502
PrimaryPart 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Anemia , Grade 0, Grade 101024201302252201
Anemia , Grade 0, Grade 210000000010144400
Anemia , Grade 0, Grade 300000000000010200
Anemia , Grade 0, Grade 400000000000000000
Anemia , Grade 1, Grade 000000000000000000
Anemia , Grade 1, Grade 203212200211192701
Anemia , Grade 1, Grade 300021000100050300
Anemia , Grade 1, Grade 400000000000000000
Anemia , Grade 2, Grade 000000000000000000
Anemia , Grade 2, Grade 100000000000000000
Anemia , Grade 2, Grade 300010000010141000
Anemia , Grade 2, Grade 400000000000000000
Anemia , Grade 3, Grade 000000000000000000
Anemia , Grade 3, Grade 100000000000000000
Anemia , Grade 3, Grade 200000000000000000
Anemia , Grade 3, Grade 400000000000000000
Anemia , Grade 4, Grade 000000000000000000
Anemia , Grade 4, Grade 100000000000000000
Anemia , Grade 4, Grade 200000000000000000
Anemia , Grade 4, Grade 300000000000000000
Hemoglobin Increased, Grade 0, Grade 100000000000010000
Hemoglobin Increased, Grade 0, Grade 200000000000000000
Hemoglobin Increased, Grade 0, Grade 300000000000100000
Hemoglobin Increased, Grade 0, Grade 400000000000000000
Hemoglobin Increased, Grade 1, Grade 000000000000000000
Hemoglobin Increased, Grade 1, Grade 200000000000000000
Hemoglobin Increased, Grade 1, Grade 300000000000000000
Hemoglobin Increased, Grade 1, Grade 400000000000000000
Hemoglobin Increased, Grade 2, Grade 000000000000000000
Hemoglobin Increased, Grade 2, Grade 100000000000000000
Hemoglobin Increased, Grade 2, Grade 300000000000000000
Hemoglobin Increased, Grade 2, Grade 400000000000000000
Hemoglobin Increased, Grade 3, Grade 000000000000000000
Hemoglobin Increased, Grade 3, Grade 100000000000000000
Hemoglobin Increased, Grade 3, Grade 200000000000000000
Hemoglobin Increased, Grade 3, Grade 400000000000000000
Hemoglobin Increased, Grade 4, Grade 000000000000000000
Hemoglobin Increased, Grade 4, Grade 100000000000000000
Hemoglobin Increased, Grade 4, Grade 200000000000000000
Hemoglobin Increased, Grade 4, Grade 300000000000000000
Lymphocyte Count Decreased, Grade 0, Grade 102012200011080000
Lymphocyte Count Decreased, Grade 0, Grade 220110000200173300
Lymphocyte Count Decreased, Grade 0, Grade 300000100000031300
Lymphocyte Count Decreased, Grade 0, Grade 400000000000010000
Lymphocyte Count Decreased, Grade 1, Grade 000010000000000000
Lymphocyte Count Decreased, Grade 1, Grade 211102100401132300
Lymphocyte Count Decreased, Grade 1, Grade 300010000000252400
Lymphocyte Count Decreased, Grade 1, Grade 400000000000010000
Lymphocyte Count Decreased, Grade 2, Grade 000000000000000000
Lymphocyte Count Decreased, Grade 2, Grade 100000000000000000
Lymphocyte Count Decreased, Grade 2, Grade 310001000010001400
Lymphocyte Count Decreased, Grade 2, Grade 400000000100001000
Lymphocyte Count Decreased, Grade 3, Grade 000000000000000000
Lymphocyte Count Decreased, Grade 3, Grade 100000000000000000
Lymphocyte Count Decreased, Grade 3, Grade 200000001100000001
Lymphocyte Count Decreased, Grade 3, Grade 400100000010000000
Lymphocyte Count Decreased, Grade 4, Grade 000000000000000000
Lymphocyte Count Decreased, Grade 4, Grade 100000000000000000
Lymphocyte Count Decreased, Grade 4, Grade 200000000000000000
Lymphocyte Count Decreased, Grade 4, Grade 300000000000000000
Lymphocyte Count Increased, Grade 0, Grade 100000000000000000
Lymphocyte Count Increased, Grade 0, Grade 201100100000000000
Lymphocyte Count Increased, Grade 0, Grade 300010000000000100
Lymphocyte Count Increased, Grade 0, Grade 400000000000000000
Lymphocyte Count Increased, Grade 1, Grade 000000000000000000
Lymphocyte Count Increased, Grade 1, Grade 200000000000000000
Lymphocyte Count Increased, Grade 1, Grade 300000000000000000
Lymphocyte Count Increased, Grade 1, Grade 400000000000000000
Lymphocyte Count Increased, Grade 2, Grade 000000000000000000
Lymphocyte Count Increased, Grade 2, Grade 100000000000000000
Lymphocyte Count Increased, Grade 2, Grade 300000000000000000
Lymphocyte Count Increased, Grade 2, Grade 400000000000000000
Lymphocyte Count Increased, Grade 3, Grade 000000000000000000
Lymphocyte Count Increased, Grade 3, Grade 100000000000000000
Lymphocyte Count Increased, Grade 3, Grade 200000000000000000
Lymphocyte Count Increased, Grade 3, Grade 400000000000000000
Lymphocyte Count Increased, Grade 4, Grade 000000000000000000
Lymphocyte Count Increased, Grade 4, Grade 100000000000000000
Lymphocyte Count Increased, Grade 4, Grade 200000000000000000
Lymphocyte Count Increased, Grade 4, Grade 300000000000000000
Neutrophil Count Decreased, Grade 0, Grade 100110200010011000
Neutrophil Count Decreased, Grade 0, Grade 200100000000182300
Neutrophil Count Decreased, Grade 0, Grade 3000000001001851000
Neutrophil Count Decreased, Grade 0, Grade 400000000000082400
Neutrophil Count Decreased, Grade 1, Grade 000000000000000000
Neutrophil Count Decreased, Grade 1, Grade 210000000000010000
Neutrophil Count Decreased, Grade 1, Grade 300000000000220000
Neutrophil Count Decreased, Grade 1, Grade 400000000000000000
Neutrophil Count Decreased, Grade 2, Grade 000000000000000000
Neutrophil Count Decreased, Grade 2, Grade 100000000000000000
Neutrophil Count Decreased, Grade 2, Grade 300000000000000000
Neutrophil Count Decreased, Grade 2, Grade 400000000000000000
Neutrophil Count Decreased, Grade 3, Grade 000000000000000000
Neutrophil Count Decreased, Grade 3, Grade 100000000000000000
Neutrophil Count Decreased, Grade 3, Grade 200000000000000000
Neutrophil Count Decreased, Grade 3, Grade 400000000000000000
Neutrophil Count Decreased, Grade 4, Grade 000000000000000000
Neutrophil Count Decreased, Grade 4, Grade 100000000000000000
Neutrophil Count Decreased, Grade 4, Grade 200000000000000000
Neutrophil Count Decreased, Grade 4, Grade 300000000000000000
Platelet Count Decreased, Grade 0, Grade 1110100000001136410
Platelet Count Decreased, Grade 0, Grade 200000000000012300
Platelet Count Decreased, Grade 0, Grade 300000000000141100
Platelet Count Decreased, Grade 0, Grade 400001000010030200
Platelet Count Decreased, Grade 1, Grade 000000000000000000
Platelet Count Decreased, Grade 1, Grade 200000000000000000
Platelet Count Decreased, Grade 1, Grade 300100000000000000
Platelet Count Decreased, Grade 1, Grade 400000000010010100
Platelet Count Decreased, Grade 2, Grade 000000000000000000
Platelet Count Decreased, Grade 2, Grade 100000000000000000
Platelet Count Decreased, Grade 2, Grade 300000000000000000
Platelet Count Decreased, Grade 2, Grade 400000000000000000
Platelet Count Decreased, Grade 3, Grade 000000000000000000
Platelet Count Decreased, Grade 3, Grade 100000000000000000
Platelet Count Decreased, Grade 3, Grade 200000000000000000
Platelet Count Decreased, Grade 3, Grade 400000000000000000
Platelet Count Decreased, Grade 4, Grade 000000000000000000
Platelet Count Decreased, Grade 4, Grade 100000000000000100
Platelet Count Decreased, Grade 4, Grade 200000000000000000
Platelet Count Decreased, Grade 4, Grade 300000000000000000
White Blood Cell Decreased, Grade 0, Grade 110212100010040500
White Blood Cell Decreased, Grade 0, Grade 2001000000002116500
White Blood Cell Decreased, Grade 0, Grade 3000000001000133700
White Blood Cell Decreased, Grade 0, Grade 400000000000001200
White Blood Cell Decreased, Grade 1, Grade 000000000000000001
White Blood Cell Decreased, Grade 1, Grade 200000000000010000
White Blood Cell Decreased, Grade 1, Grade 300000000000211100
White Blood Cell Decreased, Grade 1, Grade 400000000000010000
White Blood Cell Decreased, Grade 2, Grade 000000000000000000
White Blood Cell Decreased, Grade 2, Grade 100000000000000000
White Blood Cell Decreased, Grade 2, Grade 300000000000000000
White Blood Cell Decreased, Grade 2, Grade 400000000000000000
White Blood Cell Decreased, Grade 3, Grade 000000000000000000
White Blood Cell Decreased, Grade 3, Grade 100000000000000000
White Blood Cell Decreased, Grade 3, Grade 200000000000000000
White Blood Cell Decreased, Grade 3, Grade 400000000000000000
White Blood Cell Decreased, Grade 4, Grade 000000000000000000
White Blood Cell Decreased, Grade 4, Grade 100000000000000000
White Blood Cell Decreased, Grade 4, Grade 200000000000000000
White Blood Cell Decreased, Grade 4, Grade 300000000000000000
Leukocytosis , Grade 0, Grade 100000000000000000
Leukocytosis , Grade 0, Grade 200000000000000000
Leukocytosis , Grade 0, Grade 300000000000000000
Leukocytosis , Grade 0, Grade 400000000000000000
Leukocytosis , Grade 1, Grade 000000000000000000
Leukocytosis , Grade 1, Grade 200000000000000000
Leukocytosis , Grade 1, Grade 300000000000000000
Leukocytosis , Grade 1, Grade 400000000000000000
Leukocytosis , Grade 2, Grade 000000000000000000
Leukocytosis , Grade 2, Grade 100000000000000000
Leukocytosis , Grade 2, Grade 300000000000000000
Leukocytosis , Grade 2, Grade 400000000000000000
Leukocytosis , Grade 3, Grade 000000000000000000
Leukocytosis , Grade 3, Grade 100000000000000000
Leukocytosis , Grade 3, Grade 200000000000000000
Leukocytosis , Grade 3, Grade 400000000000000000
Leukocytosis , Grade 4, Grade 000000000000000000
Leukocytosis , Grade 4, Grade 100000000000000000
Leukocytosis , Grade 4, Grade 200000000000000000
Leukocytosis , Grade 4, Grade 300000000000000000
PrimaryPart 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Basophils, To Low00010000000021300
Basophils, To Normal or No Change5356111114114352391712
Basophils, To High01010000100033102
Eosinophils, To Low12103000200162600
Eosinophils, To Normal or No Change4235881394332371212
Eosinophils, To High00131301400136602
Hematocrit, To Low110342003023157900
Hematocrit, To Normal or No Change44556914114112161214
Hematocrit, To High00001000100120000
Monocytes, To Low0010000000001071000
Monocytes, To Normal or No Change3344991312332164614
Monocytes, To High2214220131031261300
Neutrophils, To Low——0——————————————
Neutrophils, To Normal or No Change——0——————————————
Neutrophils, To High——1——————————————
Erythrocytes, To Low1103630022231791302
Erythrocytes, To Normal or No Change4455481413212194812
Erythrocytes, To High00011000000010001
PrimaryPart 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Glucose, No Change/Decreased5448101013144353381614
Glucose, Any increase01101101100115600
Ketones, No Change/Decreased15369914143222871503
Ketones, Any increase40222200111466711
Occult Blood, No Change/Decreased34147514133232371214
Occult Blood, Any increase214446002113961000
PrimaryPart 2A: Number of Participants With Dose Modifications of Feladilimab

Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Dose Modifications of Feladilimab
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Dose delays101021001011471100
Dose escalations10010000000000000
Infusion interruptions00000000000000000
SecondaryPart 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Any AEs3411155
Any SAEs94419
SecondaryPart 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Hypoglycemia , Grade 0, Grade 1476
Hypoglycemia , Grade 0, Grade 2021
Hypoglycemia , Grade 0, Grade 3000
Hypoglycemia , Grade 0, Grade 4000
Hypoglycemia , Grade 1, Grade 0120
Hypoglycemia , Grade 1, Grade 2000
Hypoglycemia , Grade 1, Grade 3000
Hypoglycemia , Grade 1, Grade 4000
Hypoglycemia , Grade 2, Grade 0000
Hypoglycemia , Grade 2, Grade 1000
Hypoglycemia , Grade 2, Grade 3000
Hypoglycemia , Grade 2, Grade 4000
Hypoglycemia , Grade 3, Grade 0000
Hypoglycemia , Grade 3, Grade 1000
Hypoglycemia , Grade 3, Grade 2000
Hypoglycemia , Grade 3, Grade 4000
Hypoglycemia , Grade 4, Grade 0000
Hypoglycemia , Grade 4, Grade 1000
Hypoglycemia , Grade 4, Grade 2000
Hypoglycemia , Grade 4, Grade 3000
Hypoglycemia , Missing, Grade 0—22
Hypoglycemia , Missing, Grade 1—01
Hypoglycemia , Missing, Grade 2—00
Hypoglycemia , Missing, Grade 3—00
Hypoglycemia , Missing, Grade 4—00
Hyperglycemia , Grade 0, Grade 1113819
Hyperglycemia , Grade 0, Grade 2183
Hyperglycemia , Grade 0, Grade 3000
Hyperglycemia , Grade 0, Grade 4000
Hyperglycemia , Grade 1, Grade 0201
Hyperglycemia , Grade 1, Grade 2014
Hyperglycemia , Grade 1, Grade 3020
Hyperglycemia , Grade 1, Grade 4010
Hyperglycemia , Grade 2, Grade 0000
Hyperglycemia , Grade 2, Grade 1010
Hyperglycemia , Grade 2, Grade 3000
Hyperglycemia , Grade 2, Grade 4000
Hyperglycemia , Grade 3, Grade 0000
Hyperglycemia , Grade 3, Grade 1000
Hyperglycemia , Grade 3, Grade 2001
Hyperglycemia , Grade 3, Grade 4000
Hyperglycemia , Grade 4, Grade 0000
Hyperglycemia , Grade 4, Grade 1000
Hyperglycemia , Grade 4, Grade 2000
Hyperglycemia , Grade 4, Grade 3000
Hyperglycemia , Missing, Grade 0—13
Hyperglycemia , Missing, Grade 1—10
Hyperglycemia , Missing, Grade 2—00
Hyperglycemia , Missing, Grade 3—00
Hyperglycemia , Missing, Grade 4—00
Hypoalbuminemia , Grade 0, Grade 141210
Hypoalbuminemia , Grade 0, Grade 21122
Hypoalbuminemia , Grade 0, Grade 3001
Hypoalbuminemia , Grade 0, Grade 4000
Hypoalbuminemia , Grade 1, Grade 0111
Hypoalbuminemia , Grade 1, Grade 2252
Hypoalbuminemia , Grade 1, Grade 3010
Hypoalbuminemia , Grade 1, Grade 4000
Hypoalbuminemia , Grade 2, Grade 0000
Hypoalbuminemia , Grade 2, Grade 1001
Hypoalbuminemia , Grade 2, Grade 3021
Hypoalbuminemia , Grade 2, Grade 4000
Hypoalbuminemia , Grade 3, Grade 0001
Hypoalbuminemia , Grade 3, Grade 1000
Hypoalbuminemia , Grade 3, Grade 2000
Hypoalbuminemia , Grade 3, Grade 4000
Hypoalbuminemia , Grade 4, Grade 0000
Hypoalbuminemia , Grade 4, Grade 1000
Hypoalbuminemia , Grade 4, Grade 2000
Hypoalbuminemia , Grade 4, Grade 3000
Hypoalbuminemia , Missing, Grade 0—1—
Hypoalbuminemia , Missing, Grade 1—0—
Hypoalbuminemia , Missing, Grade 2—0—
Hypoalbuminemia , Missing, Grade 3—0—
Hypoalbuminemia , Missing, Grade 4—0—
AP Increased, Grade 0, Grade 17208
AP Increased, Grade 0, Grade 2230
AP Increased, Grade 0, Grade 3000
AP Increased, Grade 0, Grade 4000
AP Increased, Grade 1, Grade 0012
AP Increased, Grade 1, Grade 2391
AP Increased, Grade 1, Grade 3011
AP Increased, Grade 1, Grade 4000
AP Increased, Grade 2, Grade 0000
AP Increased, Grade 2, Grade 1000
AP Increased, Grade 2, Grade 3100
AP Increased, Grade 2, Grade 4000
AP Increased, Grade 3, Grade 0000
AP Increased, Grade 3, Grade 1000
AP Increased, Grade 3, Grade 2000
AP Increased, Grade 3, Grade 4000
AP Increased, Grade 4, Grade 0000
AP Increased, Grade 4, Grade 1000
AP Increased, Grade 4, Grade 2000
AP Increased, Grade 4, Grade 3000
AP Increased, Missing, Grade 01——
AP Increased, Missing, Grade 10——
AP Increased, Missing, Grade 20——
AP Increased, Missing, Grade 30——
AP Increased, Missing, Grade 40——
ALT Increased, Grade 0, Grade 14188
ALT Increased, Grade 0, Grade 2021
ALT Increased, Grade 0, Grade 3011
ALT Increased, Grade 0, Grade 4000
ALT Increased, Grade 1, Grade 0020
ALT Increased, Grade 1, Grade 2201
ALT Increased, Grade 1, Grade 3020
ALT Increased, Grade 1, Grade 4000
ALT Increased, Grade 2, Grade 0000
ALT Increased, Grade 2, Grade 1000
ALT Increased, Grade 2, Grade 3000
ALT Increased, Grade 2, Grade 4000
ALT Increased, Grade 3, Grade 0000
ALT Increased, Grade 3, Grade 1000
ALT Increased, Grade 3, Grade 2000
ALT Increased, Grade 3, Grade 4000
ALT Increased, Grade 4, Grade 0000
ALT Increased, Grade 4, Grade 1000
ALT Increased, Grade 4, Grade 2000
ALT Increased, Grade 4, Grade 3000
ALT Increased, Missing, Grade 0——1
ALT Increased, Missing, Grade 1——0
ALT Increased, Missing, Grade 2——0
ALT Increased, Missing, Grade 3——0
ALT Increased, Missing, Grade 4——0
AST Increased, Grade 0, Grade 192515
AST Increased, Grade 0, Grade 2001
AST Increased, Grade 0, Grade 3032
AST Increased, Grade 0, Grade 4000
AST Increased, Grade 1, Grade 0010
AST Increased, Grade 1, Grade 2110
AST Increased, Grade 1, Grade 3010
AST Increased, Grade 1, Grade 4000
AST Increased, Grade 2, Grade 0000
AST Increased, Grade 2, Grade 1010
AST Increased, Grade 2, Grade 3000
AST Increased, Grade 2, Grade 4000
AST Increased, Grade 3, Grade 0000
AST Increased, Grade 3, Grade 1000
AST Increased, Grade 3, Grade 2000
AST Increased, Grade 3, Grade 4000
AST Increased, Grade 4, Grade 0000
AST Increased, Grade 4, Grade 1000
AST Increased, Grade 4, Grade 2000
AST Increased, Grade 4, Grade 3000
AST Increased, Missing, Grade 0—1—
AST Increased, Missing, Grade 1—0—
AST Increased, Missing, Grade 2—0—
AST Increased, Missing, Grade 3—0—
AST Increased, Missing, Grade 4—0—
Blood Bilirubin Increased, Grade 0, Grade 1221
Blood Bilirubin Increased, Grade 0, Grade 2010
Blood Bilirubin Increased, Grade 0, Grade 3113
Blood Bilirubin Increased, Grade 0, Grade 4011
Blood Bilirubin Increased, Grade 1, Grade 0010
Blood Bilirubin Increased, Grade 1, Grade 2000
Blood Bilirubin Increased, Grade 1, Grade 3000
Blood Bilirubin Increased, Grade 1, Grade 4000
Blood Bilirubin Increased, Grade 2, Grade 0000
Blood Bilirubin Increased, Grade 2, Grade 1000
Blood Bilirubin Increased, Grade 2, Grade 3000
Blood Bilirubin Increased, Grade 2, Grade 4000
Blood Bilirubin Increased, Grade 3, Grade 0000
Blood Bilirubin Increased, Grade 3, Grade 1000
Blood Bilirubin Increased, Grade 3, Grade 2000
Blood Bilirubin Increased, Grade 3, Grade 4000
Blood Bilirubin Increased, Grade 4, Grade 0000
Blood Bilirubin Increased, Grade 4, Grade 1000
Blood Bilirubin Increased, Grade 4, Grade 2000
Blood Bilirubin Increased, Grade 4, Grade 3000
Blood Bilirubin Increased, Missing, Grade 0—2—
Blood Bilirubin Increased, Missing, Grade 1—0—
Blood Bilirubin Increased, Missing, Grade 2—0—
Blood Bilirubin Increased, Missing, Grade 3—1—
Blood Bilirubin Increased, Missing, Grade 4—0—
Creatinine Increased, Grade 0, Grade 12119
Creatinine Increased, Grade 0, Grade 2001
Creatinine Increased, Grade 0, Grade 3020
Creatinine Increased, Grade 0, Grade 4010
Creatinine Increased, Grade 1, Grade 0021
Creatinine Increased, Grade 1, Grade 2140
Creatinine Increased, Grade 1, Grade 3000
Creatinine Increased, Grade 1, Grade 4000
Creatinine Increased, Grade 2, Grade 0000
Creatinine Increased, Grade 2, Grade 1000
Creatinine Increased, Grade 2, Grade 3000
Creatinine Increased, Grade 2, Grade 4000
Creatinine Increased, Grade 3, Grade 0000
Creatinine Increased, Grade 3, Grade 1000
Creatinine Increased, Grade 3, Grade 2000
Creatinine Increased, Grade 3, Grade 4000
Creatinine Increased, Grade 4, Grade 0000
Creatinine Increased, Grade 4, Grade 1000
Creatinine Increased, Grade 4, Grade 2000
Creatinine Increased, Grade 4, Grade 3000
Creatinine Increased, Missing, Grade 03—1
Creatinine Increased, Missing, Grade 10—0
Creatinine Increased, Missing, Grade 20—0
Creatinine Increased, Missing, Grade 30—0
Creatinine Increased, Missing, Grade 40—0
Hypokalemia , Grade 0, Grade 1274
Hypokalemia , Grade 0, Grade 2000
Hypokalemia , Grade 0, Grade 3101
Hypokalemia , Grade 0, Grade 4010
Hypokalemia , Grade 1, Grade 0000
Hypokalemia , Grade 1, Grade 2000
Hypokalemia , Grade 1, Grade 3001
Hypokalemia , Grade 1, Grade 4000
Hypokalemia , Grade 2, Grade 0000
Hypokalemia , Grade 2, Grade 1000
Hypokalemia , Grade 2, Grade 3000
Hypokalemia , Grade 2, Grade 4000
Hypokalemia , Grade 3, Grade 0000
Hypokalemia , Grade 3, Grade 1000
Hypokalemia , Grade 3, Grade 2000
Hypokalemia , Grade 3, Grade 4000
Hypokalemia , Grade 4, Grade 0000
Hypokalemia , Grade 4, Grade 1000
Hypokalemia , Grade 4, Grade 2000
Hypokalemia , Grade 4, Grade 3000
Hyperkalemia , Grade 0, Grade 11196
Hyperkalemia , Grade 0, Grade 2252
Hyperkalemia , Grade 0, Grade 3010
Hyperkalemia , Grade 0, Grade 4102
Hyperkalemia , Grade 1, Grade 0001
Hyperkalemia , Grade 1, Grade 2000
Hyperkalemia , Grade 1, Grade 3000
Hyperkalemia , Grade 1, Grade 4000
Hyperkalemia , Grade 2, Grade 0000
Hyperkalemia , Grade 2, Grade 1000
Hyperkalemia , Grade 2, Grade 3000
Hyperkalemia , Grade 2, Grade 4000
Hyperkalemia , Grade 3, Grade 0000
Hyperkalemia , Grade 3, Grade 1000
Hyperkalemia , Grade 3, Grade 2000
Hyperkalemia , Grade 3, Grade 4000
Hyperkalemia , Grade 4, Grade 0000
Hyperkalemia , Grade 4, Grade 1000
Hyperkalemia , Grade 4, Grade 2000
Hyperkalemia , Grade 4, Grade 3000
Hyponatremia , Grade 0, Grade 172412
Hyponatremia , Grade 0, Grade 2000
Hyponatremia , Grade 0, Grade 3143
Hyponatremia , Grade 0, Grade 4112
Hyponatremia , Grade 1, Grade 0110
Hyponatremia , Grade 1, Grade 2000
Hyponatremia , Grade 1, Grade 3020
Hyponatremia , Grade 1, Grade 4001
Hyponatremia , Grade 2, Grade 0000
Hyponatremia , Grade 2, Grade 1000
Hyponatremia , Grade 2, Grade 3000
Hyponatremia , Grade 2, Grade 4000
Hyponatremia , Grade 3, Grade 0001
Hyponatremia , Grade 3, Grade 1000
Hyponatremia , Grade 3, Grade 2000
Hyponatremia , Grade 3, Grade 4000
Hyponatremia , Grade 4, Grade 0000
Hyponatremia , Grade 4, Grade 1000
Hyponatremia , Grade 4, Grade 2000
Hyponatremia , Grade 4, Grade 3000
Hypernatremia , Grade 0, Grade 1351
Hypernatremia , Grade 0, Grade 2000
Hypernatremia , Grade 0, Grade 3000
Hypernatremia , Grade 0, Grade 4000
Hypernatremia , Grade 1, Grade 0000
Hypernatremia , Grade 1, Grade 2000
Hypernatremia , Grade 1, Grade 3000
Hypernatremia , Grade 1, Grade 4000
Hypernatremia , Grade 2, Grade 0000
Hypernatremia , Grade 2, Grade 1000
Hypernatremia , Grade 2, Grade 3000
Hypernatremia , Grade 2, Grade 4000
Hypernatremia , Grade 3, Grade 0000
Hypernatremia , Grade 3, Grade 1000
Hypernatremia , Grade 3, Grade 2000
Hypernatremia , Grade 3, Grade 4000
Hypernatremia , Grade 4, Grade 0000
Hypernatremia , Grade 4, Grade 1000
Hypernatremia , Grade 4, Grade 2000
Hypernatremia , Grade 4, Grade 3000
Hypocalcemia , Grade 0, Grade 1193
Hypocalcemia , Grade 0, Grade 2100
Hypocalcemia , Grade 0, Grade 3021
Hypocalcemia , Grade 0, Grade 4210
Hypocalcemia , Grade 1, Grade 0022
Hypocalcemia , Grade 1, Grade 2000
Hypocalcemia , Grade 1, Grade 3000
Hypocalcemia , Grade 1, Grade 4000
Hypocalcemia , Grade 2, Grade 0010
Hypocalcemia , Grade 2, Grade 1010
Hypocalcemia , Grade 2, Grade 3000
Hypocalcemia , Grade 2, Grade 4000
Hypocalcemia , Grade 3, Grade 0000
Hypocalcemia , Grade 3, Grade 1000
Hypocalcemia , Grade 3, Grade 2000
Hypocalcemia , Grade 3, Grade 4000
Hypocalcemia , Grade 4, Grade 0000
Hypocalcemia , Grade 4, Grade 1000
Hypocalcemia , Grade 4, Grade 2000
Hypocalcemia , Grade 4, Grade 3000
Hypocalcemia , Missing, Grade 0—1—
Hypocalcemia , Missing, Grade 1—0—
Hypocalcemia , Missing, Grade 2—0—
Hypocalcemia , Missing, Grade 3—0—
Hypocalcemia , Missing, Grade 4—0—
Hypercalcemia , Grade 0, Grade 1556
Hypercalcemia , Grade 0, Grade 2001
Hypercalcemia , Grade 0, Grade 3011
Hypercalcemia , Grade 0, Grade 4010
Hypercalcemia , Grade 1, Grade 0000
Hypercalcemia , Grade 1, Grade 2020
Hypercalcemia , Grade 1, Grade 3011
Hypercalcemia , Grade 1, Grade 4000
Hypercalcemia , Grade 2, Grade 0001
Hypercalcemia , Grade 2, Grade 1000
Hypercalcemia , Grade 2, Grade 3001
Hypercalcemia , Grade 2, Grade 4000
Hypercalcemia , Grade 3, Grade 0000
Hypercalcemia , Grade 3, Grade 1000
Hypercalcemia , Grade 3, Grade 2000
Hypercalcemia , Grade 3, Grade 4100
Hypercalcemia , Grade 4, Grade 0000
Hypercalcemia , Grade 4, Grade 1000
Hypercalcemia , Grade 4, Grade 2000
Hypercalcemia , Grade 4, Grade 3000
Hypercalcemia , Missing, Grade 0—1—
Hypercalcemia , Missing, Grade 1—0—
Hypercalcemia , Missing, Grade 2—0—
Hypercalcemia , Missing, Grade 3—0—
Hypercalcemia , Missing, Grade 4—0—
Chronic Kidney Disease , Grade 0, Grade 1000
Chronic Kidney Disease , Grade 0, Grade 2140
Chronic Kidney Disease , Grade 0, Grade 3000
Chronic Kidney Disease , Grade 0, Grade 4013
Chronic Kidney Disease , Grade 1, Grade 0010
Chronic Kidney Disease , Grade 1, Grade 2020
Chronic Kidney Disease , Grade 1, Grade 3000
Chronic Kidney Disease , Grade 1, Grade 4000
Chronic Kidney Disease , Grade 2, Grade 0000
Chronic Kidney Disease , Grade 2, Grade 1010
Chronic Kidney Disease , Grade 2, Grade 2172
Chronic Kidney Disease , Grade 2, Grade 3010
Chronic Kidney Disease , Grade 2, Grade 4000
Chronic Kidney Disease , Grade 3, Grade 0000
Chronic Kidney Disease , Grade 3, Grade 1000
Chronic Kidney Disease , Grade 3, Grade 2000
Chronic Kidney Disease , Grade 3, Grade 4000
Chronic Kidney Disease , Grade 4, Grade 0000
Chronic Kidney Disease , Grade 4, Grade 1000
Chronic Kidney Disease , Grade 4, Grade 2000
Chronic Kidney Disease , Grade 4, Grade 3000
Chronic Kidney Disease , Missing, Grade 0120
Chronic Kidney Disease , Missing, Grade 1143
Chronic Kidney Disease , Missing, Grade 2011
Chronic Kidney Disease , Missing, Grade 3000
Chronic Kidney Disease , Missing, Grade 4010
SecondaryPart 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Lactate Dehydrogenase (IU/L), To Low0—0
Lactate Dehydrogenase (IU/L), To Normal or No Change1—3
Lactate Dehydrogenase (IU/L), To High0—1
Protein (g/L), To Low1229
Protein (g/L), To Normal or No Change348045
Protein (g/L), To High2114
Triiodothyronine, Free (pmol/L), To Low51510
Triiodothyronine, Free (pmol/L), To Normal or No Change237437
Triiodothyronine, Free (pmol/L), To High2164
Thyroxine, Free (pmol/L), To Low2145
Thyroxine, Free (pmol/L), To Normal or No Change277844
Thyroxine, Free (pmol/L), To High2122
Troponin I (ug/L), To Low010
Troponin I (ug/L), To Normal or No Change122715
Troponin I (ug/L), To High264
Troponin T (ug/L), To Low000
Troponin T (ug/L), To Normal or No Change183530
Troponin T (ug/L), To High182
Thyrotropin (mU/L), To Low341
Thyrotropin (mU/L), To Normal or No Change238241
Thyrotropin (mU/L), To High5199
Urea (mmol/L), To Low1102
Urea (mmol/L), To Normal or No Change265328
Urea (mmol/L), To High6309
SecondaryPart 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Anemia , Grade 0, Grade 14227
Anemia , Grade 0, Grade 2275
Anemia , Grade 0, Grade 3041
Anemia , Grade 0, Grade 4000
Anemia , Grade 1, Grade 0011
Anemia , Grade 1, Grade 26208
Anemia , Grade 1, Grade 3021
Anemia , Grade 1, Grade 4000
Anemia , Grade 2, Grade 0000
Anemia , Grade 2, Grade 1000
Anemia , Grade 2, Grade 3184
Anemia , Grade 2, Grade 4000
Anemia , Grade 3, Grade 0000
Anemia , Grade 3, Grade 1000
Anemia , Grade 3, Grade 2000
Anemia , Grade 3, Grade 4000
Anemia , Grade 4, Grade 0000
Anemia , Grade 4, Grade 1000
Anemia , Grade 4, Grade 2000
Anemia , Grade 4, Grade 3000
Hemoglobin Increased, Grade 0, Grade 1000
Hemoglobin Increased, Grade 0, Grade 2000
Hemoglobin Increased, Grade 0, Grade 3001
Hemoglobin Increased, Grade 0, Grade 4000
Hemoglobin Increased, Grade 1, Grade 0000
Hemoglobin Increased, Grade 1, Grade 2000
Hemoglobin Increased, Grade 1, Grade 3000
Hemoglobin Increased, Grade 1, Grade 4000
Hemoglobin Increased, Grade 2, Grade 0000
Hemoglobin Increased, Grade 2, Grade 1000
Hemoglobin Increased, Grade 2, Grade 3000
Hemoglobin Increased, Grade 2, Grade 4000
Hemoglobin Increased, Grade 3, Grade 0000
Hemoglobin Increased, Grade 3, Grade 1000
Hemoglobin Increased, Grade 3, Grade 2000
Hemoglobin Increased, Grade 3, Grade 4000
Hemoglobin Increased, Grade 4, Grade 0000
Hemoglobin Increased, Grade 4, Grade 1000
Hemoglobin Increased, Grade 4, Grade 2000
Hemoglobin Increased, Grade 4, Grade 3000
Lymphocyte Count Decreased, Grade 0, Grade 12228
Lymphocyte Count Decreased, Grade 0, Grade 21106
Lymphocyte Count Decreased, Grade 0, Grade 3010
Lymphocyte Count Decreased, Grade 0, Grade 4010
Lymphocyte Count Decreased, Grade 1, Grade 0110
Lymphocyte Count Decreased, Grade 1, Grade 25157
Lymphocyte Count Decreased, Grade 1, Grade 3141
Lymphocyte Count Decreased, Grade 1, Grade 4000
Lymphocyte Count Decreased, Grade 2, Grade 0000
Lymphocyte Count Decreased, Grade 2, Grade 1100
Lymphocyte Count Decreased, Grade 2, Grade 3323
Lymphocyte Count Decreased, Grade 2, Grade 4000
Lymphocyte Count Decreased, Grade 3, Grade 0000
Lymphocyte Count Decreased, Grade 3, Grade 1000
Lymphocyte Count Decreased, Grade 3, Grade 2000
Lymphocyte Count Decreased, Grade 3, Grade 4000
Lymphocyte Count Decreased, Grade 4, Grade 0000
Lymphocyte Count Decreased, Grade 4, Grade 1000
Lymphocyte Count Decreased, Grade 4, Grade 2000
Lymphocyte Count Decreased, Grade 4, Grade 3000
Lymphocyte Count Decreased, Missing, Grade 0—0—
Lymphocyte Count Decreased, Missing, Grade 1—1—
Lymphocyte Count Decreased, Missing, Grade 2—3—
Lymphocyte Count Decreased, Missing, Grade 3—0—
Lymphocyte Count Decreased, Missing, Grade 4—0—
Lymphocyte Count Increased, Grade 0, Grade 1000
Lymphocyte Count Increased, Grade 0, Grade 2040
Lymphocyte Count Increased, Grade 0, Grade 3011
Lymphocyte Count Increased, Grade 0, Grade 4000
Lymphocyte Count Increased, Grade 1, Grade 0000
Lymphocyte Count Increased, Grade 1, Grade 2000
Lymphocyte Count Increased, Grade 1, Grade 3000
Lymphocyte Count Increased, Grade 1, Grade 4000
Lymphocyte Count Increased, Grade 2, Grade 0000
Lymphocyte Count Increased, Grade 2, Grade 1000
Lymphocyte Count Increased, Grade 2, Grade 3000
Lymphocyte Count Increased, Grade 2, Grade 4000
Lymphocyte Count Increased, Grade 3, Grade 0000
Lymphocyte Count Increased, Grade 3, Grade 1000
Lymphocyte Count Increased, Grade 3, Grade 2010
Lymphocyte Count Increased, Grade 3, Grade 4000
Lymphocyte Count Increased, Grade 4, Grade 0000
Lymphocyte Count Increased, Grade 4, Grade 1000
Lymphocyte Count Increased, Grade 4, Grade 2000
Lymphocyte Count Increased, Grade 4, Grade 3000
Lymphocyte Count Increased, Missing, Grade 0—3—
Lymphocyte Count Increased, Missing, Grade 1—0—
Lymphocyte Count Increased, Missing, Grade 2—1—
Lymphocyte Count Increased, Missing, Grade 3—0—
Lymphocyte Count Increased, Missing, Grade 4—0—
Neutrophil Count Decreased, Grade 0, Grade 1142
Neutrophil Count Decreased, Grade 0, Grade 2003
Neutrophil Count Decreased, Grade 0, Grade 3010
Neutrophil Count Decreased, Grade 0, Grade 4010
Neutrophil Count Decreased, Grade 1, Grade 0000
Neutrophil Count Decreased, Grade 1, Grade 2000
Neutrophil Count Decreased, Grade 1, Grade 3000
Neutrophil Count Decreased, Grade 1, Grade 4000
Neutrophil Count Decreased, Grade 2, Grade 0000
Neutrophil Count Decreased, Grade 2, Grade 1000
Neutrophil Count Decreased, Grade 2, Grade 3000
Neutrophil Count Decreased, Grade 2, Grade 4000
Neutrophil Count Decreased, Grade 3, Grade 0000
Neutrophil Count Decreased, Grade 3, Grade 1000
Neutrophil Count Decreased, Grade 3, Grade 2000
Neutrophil Count Decreased, Grade 3, Grade 4000
Neutrophil Count Decreased, Grade 4, Grade 0000
Neutrophil Count Decreased, Grade 4, Grade 1000
Neutrophil Count Decreased, Grade 4, Grade 2000
Neutrophil Count Decreased, Grade 4, Grade 3000
Neutrophil Count Decreased, Missing, Grade 0—6—
Neutrophil Count Decreased, Missing, Grade 1—0—
Neutrophil Count Decreased, Missing, Grade 2—0—
Neutrophil Count Decreased, Missing, Grade 3—0—
Neutrophil Count Decreased, Missing, Grade 4—0—
Platelet Count Decreased, Grade 0, Grade 1062
Platelet Count Decreased, Grade 0, Grade 2000
Platelet Count Decreased, Grade 0, Grade 3010
Platelet Count Decreased, Grade 0, Grade 4001
Platelet Count Decreased, Grade 1, Grade 0010
Platelet Count Decreased, Grade 1, Grade 2000
Platelet Count Decreased, Grade 1, Grade 3000
Platelet Count Decreased, Grade 1, Grade 4000
Platelet Count Decreased, Grade 2, Grade 0000
Platelet Count Decreased, Grade 2, Grade 1000
Platelet Count Decreased, Grade 2, Grade 3000
Platelet Count Decreased, Grade 2, Grade 4000
Platelet Count Decreased, Grade 3, Grade 0000
Platelet Count Decreased, Grade 3, Grade 1000
Platelet Count Decreased, Grade 3, Grade 2000
Platelet Count Decreased, Grade 3, Grade 4000
Platelet Count Decreased, Grade 4, Grade 0100
Platelet Count Decreased, Grade 4, Grade 1000
Platelet Count Decreased, Grade 4, Grade 2000
Platelet Count Decreased, Grade 4, Grade 3000
Platelet Count Decreased, Missing, Grade 0—2—
Platelet Count Decreased, Missing, Grade 1—0—
Platelet Count Decreased, Missing, Grade 2—0—
Platelet Count Decreased, Missing, Grade 3—0—
Platelet Count Decreased, Missing, Grade 4—0—
White Blood Cell Decreased, Grade 0, Grade 1493
White Blood Cell Decreased, Grade 0, Grade 2012
White Blood Cell Decreased, Grade 0, Grade 3000
White Blood Cell Decreased, Grade 0, Grade 4020
White Blood Cell Decreased, Grade 1, Grade 0010
White Blood Cell Decreased, Grade 1, Grade 2122
White Blood Cell Decreased, Grade 1, Grade 3000
White Blood Cell Decreased, Grade 1, Grade 4000
White Blood Cell Decreased, Grade 2, Grade 0000
White Blood Cell Decreased, Grade 2, Grade 1000
White Blood Cell Decreased, Grade 2, Grade 3000
White Blood Cell Decreased, Grade 2, Grade 4000
White Blood Cell Decreased, Grade 3, Grade 0000
White Blood Cell Decreased, Grade 3, Grade 1000
White Blood Cell Decreased, Grade 3, Grade 2000
White Blood Cell Decreased, Grade 3, Grade 4000
White Blood Cell Decreased, Grade 4, Grade 0000
White Blood Cell Decreased, Grade 4, Grade 1000
White Blood Cell Decreased, Grade 4, Grade 2000
White Blood Cell Decreased, Grade 4, Grade 3000
Leukocytosis , Grade 0, Grade 1000
Leukocytosis , Grade 0, Grade 2000
Leukocytosis , Grade 0, Grade 3000
Leukocytosis , Grade 0, Grade 4000
Leukocytosis , Grade 1, Grade 0000
Leukocytosis , Grade 1, Grade 2000
Leukocytosis , Grade 1, Grade 3000
Leukocytosis , Grade 1, Grade 4000
Leukocytosis , Grade 2, Grade 0000
Leukocytosis , Grade 2, Grade 1000
Leukocytosis , Grade 2, Grade 3000
Leukocytosis , Grade 2, Grade 4000
Leukocytosis , Grade 3, Grade 0000
Leukocytosis , Grade 3, Grade 1000
Leukocytosis , Grade 3, Grade 2000
Leukocytosis , Grade 3, Grade 4000
Leukocytosis , Grade 4, Grade 0000
Leukocytosis , Grade 4, Grade 1000
Leukocytosis , Grade 4, Grade 2000
Leukocytosis , Grade 4, Grade 3000
SecondaryPart 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Basophils, To Low131
Basophils, To Normal or No Change3510155
Basophils, To High032
Eosinophils, To Low5117
Eosinophils, To Normal or No Change278546
Eosinophils, To High7186
Hematocrit, To Low83320
Hematocrit, To Normal or No Change287438
Hematocrit, To High270
Monocytes, To Low030
Monocytes, To Normal or No Change299243
Monocytes, To High82015
Erythrocytes, To Low82512
Erythrocytes, To Normal or No Change298545
Erythrocytes, To High041
SecondaryPart 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Glucose, No Change/Decreased3610456
Glucose, Any Increase292
Ketones, No Change/Decreased297646
Ketones, Any Increase93712
Occult Blood, No Change/Decreased247039
Occult Blood, Any Increase124019
SecondaryPart 1B: Number of Participants With Dose Modifications of Feladilimab

Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Dose Modifications of Feladilimab
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Dose delays4175
Dose escalations430
Infusion interruptions010
SecondaryPart 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Any AEs1325043234541
Any SAEs31261771221
SecondaryPart 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters

Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Hypoglycemia , Grade 0, Grade 1018510000
Hypoglycemia , Grade 0, Grade 204000000
Hypoglycemia , Grade 0, Grade 302000000
Hypoglycemia , Grade 0, Grade 402000000
Hypoglycemia , Grade 1, Grade 000101000
Hypoglycemia , Grade 1, Grade 200000000
Hypoglycemia , Grade 1, Grade 300000000
Hypoglycemia , Grade 1, Grade 400000000
Hypoglycemia , Grade 2, Grade 000000000
Hypoglycemia , Grade 2, Grade 100000000
Hypoglycemia , Grade 2, Grade 300000000
Hypoglycemia , Grade 2, Grade 401000000
Hypoglycemia , Grade 3, Grade 000000000
Hypoglycemia , Grade 3, Grade 100000000
Hypoglycemia , Grade 3, Grade 200000000
Hypoglycemia , Grade 3, Grade 400000000
Hypoglycemia , Grade 4, Grade 000000000
Hypoglycemia , Grade 4, Grade 100000000
Hypoglycemia , Grade 4, Grade 200000000
Hypoglycemia , Grade 4, Grade 300000000
Hypoglycemia , Missing, Grade 0—1——————
Hypoglycemia , Missing, Grade 1—0——————
Hypoglycemia , Missing, Grade 2—0——————
Hypoglycemia , Missing, Grade 3—0——————
Hypoglycemia , Missing, Grade 4—0——————
Hyperglycemia , Grade 0, Grade 14911261220
Hyperglycemia , Grade 0, Grade 2013021100
Hyperglycemia , Grade 0, Grade 300000000
Hyperglycemia , Grade 0, Grade 400000000
Hyperglycemia , Grade 1, Grade 005200010
Hyperglycemia , Grade 1, Grade 2122310000
Hyperglycemia , Grade 1, Grade 304000000
Hyperglycemia , Grade 1, Grade 401000000
Hyperglycemia , Grade 2, Grade 000000000
Hyperglycemia , Grade 2, Grade 102100000
Hyperglycemia , Grade 2, Grade 301000100
Hyperglycemia , Grade 2, Grade 400000000
Hyperglycemia , Grade 3, Grade 000000000
Hyperglycemia , Grade 3, Grade 100000000
Hyperglycemia , Grade 3, Grade 200010000
Hyperglycemia , Grade 3, Grade 400000000
Hyperglycemia , Grade 4, Grade 000000000
Hyperglycemia , Grade 4, Grade 101000000
Hyperglycemia , Grade 4, Grade 200000000
Hyperglycemia , Grade 4, Grade 300000000
Hyperglycemia , Missing, Grade 0—1——————
Hyperglycemia , Missing, Grade 1—0——————
Hyperglycemia , Missing, Grade 2—0——————
Hyperglycemia , Missing, Grade 3—0——————
Hyperglycemia , Missing, Grade 4—0——————
Hypoalbuminemia , Grade 0, Grade 1647761200
Hypoalbuminemia , Grade 0, Grade 2112210220
Hypoalbuminemia , Grade 0, Grade 305100000
Hypoalbuminemia , Grade 0, Grade 400000000
Hypoalbuminemia , Grade 1, Grade 000010000
Hypoalbuminemia , Grade 1, Grade 2111620100
Hypoalbuminemia , Grade 1, Grade 300000000
Hypoalbuminemia , Grade 1, Grade 400000000
Hypoalbuminemia , Grade 2, Grade 000000000
Hypoalbuminemia , Grade 2, Grade 100000000
Hypoalbuminemia , Grade 2, Grade 304000000
Hypoalbuminemia , Grade 2, Grade 400000000
Hypoalbuminemia , Grade 3, Grade 000000000
Hypoalbuminemia , Grade 3, Grade 100000000
Hypoalbuminemia , Grade 3, Grade 200000000
Hypoalbuminemia , Grade 3, Grade 400000000
Hypoalbuminemia , Grade 4, Grade 000000000
Hypoalbuminemia , Grade 4, Grade 100000000
Hypoalbuminemia , Grade 4, Grade 200000000
Hypoalbuminemia , Grade 4, Grade 300000000
Hypoalbuminemia , Missing, Grade 0—0——————
Hypoalbuminemia , Missing, Grade 1—1——————
Hypoalbuminemia , Missing, Grade 2—0——————
Hypoalbuminemia , Missing, Grade 3—0——————
Hypoalbuminemia , Missing, Grade 4—0——————
AP Increased, Grade 0, Grade 13501120120
AP Increased, Grade 0, Grade 207100100
AP Increased, Grade 0, Grade 301100000
AP Increased, Grade 0, Grade 400000000
AP Increased, Grade 1, Grade 000000000
AP Increased, Grade 1, Grade 2110320010
AP Increased, Grade 1, Grade 301020000
AP Increased, Grade 1, Grade 400000000
AP Increased, Grade 2, Grade 000000000
AP Increased, Grade 2, Grade 100000000
AP Increased, Grade 2, Grade 303010000
AP Increased, Grade 2, Grade 400000000
AP Increased, Grade 3, Grade 000000000
AP Increased, Grade 3, Grade 100000000
AP Increased, Grade 3, Grade 200000000
AP Increased, Grade 3, Grade 401000000
AP Increased, Grade 4, Grade 000000000
AP Increased, Grade 4, Grade 100000000
AP Increased, Grade 4, Grade 200000000
AP Increased, Grade 4, Grade 300000000
ALT Increased, Grade 0, Grade 1250840120
ALT Increased, Grade 0, Grade 216000000
ALT Increased, Grade 0, Grade 302200100
ALT Increased, Grade 0, Grade 401000000
ALT Increased, Grade 1, Grade 001100000
ALT Increased, Grade 1, Grade 201010000
ALT Increased, Grade 1, Grade 302010000
ALT Increased, Grade 1, Grade 400000000
ALT Increased, Grade 2, Grade 000000000
ALT Increased, Grade 2, Grade 100000000
ALT Increased, Grade 2, Grade 310000000
ALT Increased, Grade 2, Grade 400000000
ALT Increased, Grade 3, Grade 000000000
ALT Increased, Grade 3, Grade 100000000
ALT Increased, Grade 3, Grade 200000000
ALT Increased, Grade 3, Grade 400000000
ALT Increased, Grade 4, Grade 000000000
ALT Increased, Grade 4, Grade 100000000
ALT Increased, Grade 4, Grade 200000000
ALT Increased, Grade 4, Grade 300000000
AST Increased, Grade 0, Grade 1465840020
AST Increased, Grade 0, Grade 201100100
AST Increased, Grade 0, Grade 304200000
AST Increased, Grade 0, Grade 401000000
AST Increased, Grade 1, Grade 005300000
AST Increased, Grade 1, Grade 207120000
AST Increased, Grade 1, Grade 301110000
AST Increased, Grade 1, Grade 400000000
AST Increased, Grade 2, Grade 000000000
AST Increased, Grade 2, Grade 101000000
AST Increased, Grade 2, Grade 301000000
AST Increased, Grade 2, Grade 400000000
AST Increased, Grade 3, Grade 000000000
AST Increased, Grade 3, Grade 100000000
AST Increased, Grade 3, Grade 200000000
AST Increased, Grade 3, Grade 400000000
AST Increased, Grade 4, Grade 000000000
AST Increased, Grade 4, Grade 100000000
AST Increased, Grade 4, Grade 200000000
AST Increased, Grade 4, Grade 300000000
Blood Bilirubin Increased, Grade 0, Grade 1012410000
Blood Bilirubin Increased, Grade 0, Grade 207100000
Blood Bilirubin Increased, Grade 0, Grade 301100000
Blood Bilirubin Increased, Grade 0, Grade 400100000
Blood Bilirubin Increased, Grade 1, Grade 000000000
Blood Bilirubin Increased, Grade 1, Grade 201000000
Blood Bilirubin Increased, Grade 1, Grade 311000000
Blood Bilirubin Increased, Grade 1, Grade 400000000
Blood Bilirubin Increased, Grade 2, Grade 000000000
Blood Bilirubin Increased, Grade 2, Grade 101000000
Blood Bilirubin Increased, Grade 2, Grade 300000000
Blood Bilirubin Increased, Grade 2, Grade 400000000
Blood Bilirubin Increased, Grade 3, Grade 000000000
Blood Bilirubin Increased, Grade 3, Grade 100000000
Blood Bilirubin Increased, Grade 3, Grade 200000000
Blood Bilirubin Increased, Grade 3, Grade 400000000
Blood Bilirubin Increased, Grade 4, Grade 000000000
Blood Bilirubin Increased, Grade 4, Grade 100000000
Blood Bilirubin Increased, Grade 4, Grade 200000000
Blood Bilirubin Increased, Grade 4, Grade 300000000
Blood Bilirubin Increased, Missing, Grade 0—1——————
Blood Bilirubin Increased, Missing, Grade 1—0——————
Blood Bilirubin Increased, Missing, Grade 2—0——————
Blood Bilirubin Increased, Missing, Grade 3—0——————
Blood Bilirubin Increased, Missing, Grade 4—0——————
Cpk Increased, Grade 0, Grade 1——0—————
Cpk Increased, Grade 0, Grade 2——0—————
Cpk Increased, Grade 0, Grade 3——0—————
Cpk Increased, Grade 0, Grade 4——0—————
Cpk Increased, Grade 1, Grade 0——0—————
Cpk Increased, Grade 1, Grade 2——0—————
Cpk Increased, Grade 1, Grade 3——0—————
Cpk Increased, Grade 1, Grade 4——0—————
Cpk Increased, Grade 2, Grade 0——0—————
Cpk Increased, Grade 2, Grade 1——0—————
Cpk Increased, Grade 2, Grade 3——0—————
Cpk Increased, Grade 2, Grade 4——0—————
Cpk Increased, Grade 3, Grade 0——0—————
Cpk Increased, Grade 3, Grade 1——0—————
Cpk Increased, Grade 3, Grade 2——0—————
Cpk Increased, Grade 3, Grade 4——0—————
Cpk Increased, Grade 4, Grade 0——0—————
Cpk Increased, Grade 4, Grade 1——0—————
Cpk Increased, Grade 4, Grade 2——0—————
Cpk Increased, Grade 4, Grade 3——0—————
Cpk Increased, Missing, Grade 0——1—————
Cpk Increased, Missing, Grade 1——0—————
Cpk Increased, Missing, Grade 2——0—————
Cpk Increased, Missing, Grade 3——0—————
Cpk Increased, Missing, Grade 4——0—————
Creatinine Increased, Grade 0, Grade 1224460101
Creatinine Increased, Grade 0, Grade 209100000
Creatinine Increased, Grade 0, Grade 302000000
Creatinine Increased, Grade 0, Grade 402000000
Creatinine Increased, Grade 1, Grade 002000000
Creatinine Increased, Grade 1, Grade 2012000010
Creatinine Increased, Grade 1, Grade 300000000
Creatinine Increased, Grade 1, Grade 401000000
Creatinine Increased, Grade 2, Grade 000000000
Creatinine Increased, Grade 2, Grade 100000000
Creatinine Increased, Grade 2, Grade 300000000
Creatinine Increased, Grade 2, Grade 400000000
Creatinine Increased, Grade 3, Grade 000000000
Creatinine Increased, Grade 3, Grade 100000000
Creatinine Increased, Grade 3, Grade 200000000
Creatinine Increased, Grade 3, Grade 400000000
Creatinine Increased, Grade 4, Grade 000000000
Creatinine Increased, Grade 4, Grade 100000000
Creatinine Increased, Grade 4, Grade 200000000
Creatinine Increased, Grade 4, Grade 300000000
Hypokalemia , Grade 0, Grade 1130721100
Hypokalemia , Grade 0, Grade 200000000
Hypokalemia , Grade 0, Grade 300000000
Hypokalemia , Grade 0, Grade 401000000
Hypokalemia , Grade 1, Grade 003000000
Hypokalemia , Grade 1, Grade 200000000
Hypokalemia , Grade 1, Grade 300000000
Hypokalemia , Grade 1, Grade 400000000
Hypokalemia , Grade 2, Grade 000000000
Hypokalemia , Grade 2, Grade 100000000
Hypokalemia , Grade 2, Grade 300000000
Hypokalemia , Grade 2, Grade 400000000
Hypokalemia , Grade 3, Grade 000000000
Hypokalemia , Grade 3, Grade 100000000
Hypokalemia , Grade 3, Grade 200000000
Hypokalemia , Grade 3, Grade 400000000
Hypokalemia , Grade 4, Grade 000000000
Hypokalemia , Grade 4, Grade 100000000
Hypokalemia , Grade 4, Grade 200000000
Hypokalemia , Grade 4, Grade 300000000
Hyperkalemia , Grade 0, Grade 1145640201
Hyperkalemia , Grade 0, Grade 208310000
Hyperkalemia , Grade 0, Grade 302000000
Hyperkalemia , Grade 0, Grade 404130000
Hyperkalemia , Grade 1, Grade 001001000
Hyperkalemia , Grade 1, Grade 201000000
Hyperkalemia , Grade 1, Grade 300000000
Hyperkalemia , Grade 1, Grade 400000000
Hyperkalemia , Grade 2, Grade 001000000
Hyperkalemia , Grade 2, Grade 100000000
Hyperkalemia , Grade 2, Grade 300000000
Hyperkalemia , Grade 2, Grade 400000000
Hyperkalemia , Grade 3, Grade 000000000
Hyperkalemia , Grade 3, Grade 100000000
Hyperkalemia , Grade 3, Grade 200000000
Hyperkalemia , Grade 3, Grade 400000000
Hyperkalemia , Grade 4, Grade 001000000
Hyperkalemia , Grade 4, Grade 100000000
Hyperkalemia , Grade 4, Grade 200000000
Hyperkalemia , Grade 4, Grade 300000000
Hyponatremia , Grade 0, Grade 1452580310
Hyponatremia , Grade 0, Grade 200000000
Hyponatremia , Grade 0, Grade 3010320000
Hyponatremia , Grade 0, Grade 409110000
Hyponatremia , Grade 1, Grade 002000000
Hyponatremia , Grade 1, Grade 200000000
Hyponatremia , Grade 1, Grade 311001010
Hyponatremia , Grade 1, Grade 400000000
Hyponatremia , Grade 2, Grade 000000000
Hyponatremia , Grade 2, Grade 100000000
Hyponatremia , Grade 2, Grade 300000000
Hyponatremia , Grade 2, Grade 400000000
Hyponatremia , Grade 3, Grade 000000000
Hyponatremia , Grade 3, Grade 100000000
Hyponatremia , Grade 3, Grade 200000000
Hyponatremia , Grade 3, Grade 400000000
Hyponatremia , Grade 4, Grade 000000000
Hyponatremia , Grade 4, Grade 101000000
Hyponatremia , Grade 4, Grade 200000000
Hyponatremia , Grade 4, Grade 300000000
Hypernatremia , Grade 0, Grade 109300000
Hypernatremia , Grade 0, Grade 201000000
Hypernatremia , Grade 0, Grade 300000000
Hypernatremia , Grade 0, Grade 400000000
Hypernatremia , Grade 1, Grade 003000000
Hypernatremia , Grade 1, Grade 200000000
Hypernatremia , Grade 1, Grade 300000000
Hypernatremia , Grade 1, Grade 400000000
Hypernatremia , Grade 2, Grade 000000000
Hypernatremia , Grade 2, Grade 100000000
Hypernatremia , Grade 2, Grade 300000000
Hypernatremia , Grade 2, Grade 400000000
Hypernatremia , Grade 3, Grade 000000000
Hypernatremia , Grade 3, Grade 100000000
Hypernatremia , Grade 3, Grade 200000000
Hypernatremia , Grade 3, Grade 400000000
Hypernatremia , Grade 4, Grade 000000000
Hypernatremia , Grade 4, Grade 100000000
Hypernatremia , Grade 4, Grade 200000000
Hypernatremia , Grade 4, Grade 300000000
Hypocalcemia , Grade 0, Grade 1126220100
Hypocalcemia , Grade 0, Grade 205001000
Hypocalcemia , Grade 0, Grade 301000000
Hypocalcemia , Grade 0, Grade 408000000
Hypocalcemia , Grade 1, Grade 004000001
Hypocalcemia , Grade 1, Grade 203000000
Hypocalcemia , Grade 1, Grade 301000000
Hypocalcemia , Grade 1, Grade 400000000
Hypocalcemia , Grade 2, Grade 000000000
Hypocalcemia , Grade 2, Grade 100000000
Hypocalcemia , Grade 2, Grade 300000000
Hypocalcemia , Grade 2, Grade 400000000
Hypocalcemia , Grade 3, Grade 000000000
Hypocalcemia , Grade 3, Grade 100000000
Hypocalcemia , Grade 3, Grade 200000000
Hypocalcemia , Grade 3, Grade 400000000
Hypocalcemia , Grade 4, Grade 002000000
Hypocalcemia , Grade 4, Grade 100000000
Hypocalcemia , Grade 4, Grade 200000000
Hypocalcemia , Grade 4, Grade 300000000
Hypocalcemia , Missing, Grade 0—0——————
Hypocalcemia , Missing, Grade 1—0——————
Hypocalcemia , Missing, Grade 2—0——————
Hypocalcemia , Missing, Grade 3—0——————
Hypocalcemia , Missing, Grade 4—1——————
Hypercalcemia , Grade 0, Grade 1234790020
Hypercalcemia , Grade 0, Grade 201110000
Hypercalcemia , Grade 0, Grade 301010000
Hypercalcemia , Grade 0, Grade 4010100000
Hypercalcemia , Grade 1, Grade 002000010
Hypercalcemia , Grade 1, Grade 204100000
Hypercalcemia , Grade 1, Grade 301100000
Hypercalcemia , Grade 1, Grade 400000000
Hypercalcemia , Grade 2, Grade 001000000
Hypercalcemia , Grade 2, Grade 100000000
Hypercalcemia , Grade 2, Grade 300000010
Hypercalcemia , Grade 2, Grade 400000000
Hypercalcemia , Grade 3, Grade 000000000
Hypercalcemia , Grade 3, Grade 101000000
Hypercalcemia , Grade 3, Grade 201000000
Hypercalcemia , Grade 3, Grade 400010000
Hypercalcemia , Grade 4, Grade 000000000
Hypercalcemia , Grade 4, Grade 100000000
Hypercalcemia , Grade 4, Grade 200000000
Hypercalcemia , Grade 4, Grade 300000000
Hypercalcemia , Missing, Grade 0—0——————
Hypercalcemia , Missing, Grade 1—0——————
Hypercalcemia , Missing, Grade 2—0——————
Hypercalcemia , Missing, Grade 3—0——————
Hypercalcemia , Missing, Grade 4—1——————
Chronic Kidney Disease , Grade 0, Grade 10300000—
Chronic Kidney Disease , Grade 0, Grade 20501000—
Chronic Kidney Disease , Grade 0, Grade 30010000—
Chronic Kidney Disease , Grade 0, Grade 40000000—
Chronic Kidney Disease , Grade 1, Grade 00000000—
Chronic Kidney Disease , Grade 1, Grade 201100000—
Chronic Kidney Disease , Grade 1, Grade 30000000—
Chronic Kidney Disease , Grade 1, Grade 40000000—
Chronic Kidney Disease , Grade 2, Grade 00000000—
Chronic Kidney Disease , Grade 2, Grade 10000000—
Chronic Kidney Disease , Grade 2, Grade 30400000—
Chronic Kidney Disease , Grade 2, Grade 40000000—
Chronic Kidney Disease , Grade 3, Grade 00000000—
Chronic Kidney Disease , Grade 3, Grade 10000000—
Chronic Kidney Disease , Grade 3, Grade 20000000—
Chronic Kidney Disease , Grade 3, Grade 40000000—
Chronic Kidney Disease , Grade 4, Grade 00000000—
Chronic Kidney Disease , Grade 4, Grade 10000000—
Chronic Kidney Disease , Grade 4, Grade 20000000—
Chronic Kidney Disease , Grade 4, Grade 30000000—
Chronic Kidney Disease , Missing, Grade 00611——1—
Chronic Kidney Disease , Missing, Grade 12901——0—
Chronic Kidney Disease , Missing, Grade 211034——0—
Chronic Kidney Disease , Missing, Grade 30000——0—
Chronic Kidney Disease , Missing, Grade 40601——0—
SecondaryPart 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Direct Bilirubin (umol/L), To Low——0—————
Direct Bilirubin (umol/L), To Normal or No Change——0—————
Direct Bilirubin (umol/L), To High——1—————
Creatine Kinase MB (ug/L), To Low——0—————
Creatine Kinase MB (ug/L), To Normal or No Change——1—————
Creatine Kinase MB (ug/L), To High——0—————
Lactate Dehydrogenase (IU/L), To Low—001————
Lactate Dehydrogenase (IU/L), To Normal or No Change—020————
Lactate Dehydrogenase (IU/L), To High—220————
Protein (g/L), To Low137923110
Protein (g/L), To Normal or No Change1118327181421
Protein (g/L), To High238740120
Triiodothyronine, Free (pmol/L), To Low34175002—
Triiodothyronine, Free (pmol/L), To Normal or No Change101602912352—
Triiodothyronine, Free (pmol/L), To High03123100—
Thyroxine, Free (pmol/L), To Low23063100—
Thyroxine, Free (pmol/L), To Normal or No Change101803016234—
Thyroxine, Free (pmol/L), To High12521100—
Troponin I (ug/L), To Low0102000—
Troponin I (ug/L), To Normal or No Change71091812323—
Troponin I (ug/L), To High11532000—
Troponin T (ug/L), To Low—00000——
Troponin T (ug/L), To Normal or No Change—446411——
Troponin T (ug/L), To High—131100——
Thyrotropin (mU/L), To Low02212011—
Thyrotropin (mU/L), To Normal or No Change121792912343—
Thyrotropin (mU/L), To High13486010—
Urea (mmol/L), To Low23335—01—
Urea (mmol/L), To Normal or No Change91372710—13—
Urea (mmol/L), To High15364—21—
SecondaryPart 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters

Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as "Parameter name, B GX, WCPB GX" where X=grade digit.

Time frame:
Baseline (Day 1) and up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Anemia , Grade 0, Grade 14711351200
Anemia , Grade 0, Grade 219420000
Anemia , Grade 0, Grade 303100000
Anemia , Grade 0, Grade 400000000
Anemia , Grade 1, Grade 001000000
Anemia , Grade 1, Grade 2344740020
Anemia , Grade 1, Grade 3010010100
Anemia , Grade 1, Grade 400000000
Anemia , Grade 2, Grade 000000000
Anemia , Grade 2, Grade 100010000
Anemia , Grade 2, Grade 305110000
Anemia , Grade 2, Grade 400000000
Anemia , Grade 3, Grade 001000000
Anemia , Grade 3, Grade 100000000
Anemia , Grade 3, Grade 200000000
Anemia , Grade 3, Grade 400000000
Anemia , Grade 4, Grade 000000000
Anemia , Grade 4, Grade 100000000
Anemia , Grade 4, Grade 200000000
Anemia , Grade 4, Grade 300000000
Hemoglobin Increased, Grade 0, Grade 105200000
Hemoglobin Increased, Grade 0, Grade 200000000
Hemoglobin Increased, Grade 0, Grade 302110000
Hemoglobin Increased, Grade 0, Grade 400000000
Hemoglobin Increased, Grade 1, Grade 000000000
Hemoglobin Increased, Grade 1, Grade 201000000
Hemoglobin Increased, Grade 1, Grade 300000000
Hemoglobin Increased, Grade 1, Grade 400000000
Hemoglobin Increased, Grade 2, Grade 001000000
Hemoglobin Increased, Grade 2, Grade 100000000
Hemoglobin Increased, Grade 2, Grade 300000000
Hemoglobin Increased, Grade 2, Grade 400000000
Hemoglobin Increased, Grade 3, Grade 001000000
Hemoglobin Increased, Grade 3, Grade 100000000
Hemoglobin Increased, Grade 3, Grade 200000000
Hemoglobin Increased, Grade 3, Grade 400000000
Hemoglobin Increased, Grade 4, Grade 000000000
Hemoglobin Increased, Grade 4, Grade 100000000
Hemoglobin Increased, Grade 4, Grade 200000000
Hemoglobin Increased, Grade 4, Grade 300000000
Lymphocyte Count Decreased, Grade 0, Grade 1340712110
Lymphocyte Count Decreased, Grade 0, Grade 2124340000
Lymphocyte Count Decreased, Grade 0, Grade 316110000
Lymphocyte Count Decreased, Grade 0, Grade 400100000
Lymphocyte Count Decreased, Grade 1, Grade 002110000
Lymphocyte Count Decreased, Grade 1, Grade 2342951200
Lymphocyte Count Decreased, Grade 1, Grade 3016120000
Lymphocyte Count Decreased, Grade 1, Grade 402000000
Lymphocyte Count Decreased, Grade 2, Grade 000000000
Lymphocyte Count Decreased, Grade 2, Grade 101000100
Lymphocyte Count Decreased, Grade 2, Grade 307130120
Lymphocyte Count Decreased, Grade 2, Grade 401000000
Lymphocyte Count Decreased, Grade 3, Grade 000000000
Lymphocyte Count Decreased, Grade 3, Grade 100000000
Lymphocyte Count Decreased, Grade 3, Grade 200010000
Lymphocyte Count Decreased, Grade 3, Grade 410000000
Lymphocyte Count Decreased, Grade 4, Grade 000000000
Lymphocyte Count Decreased, Grade 4, Grade 100000000
Lymphocyte Count Decreased, Grade 4, Grade 200000000
Lymphocyte Count Decreased, Grade 4, Grade 300000000
Lymphocyte Count Decreased, Missing, Grade 0—1———0——
Lymphocyte Count Decreased, Missing, Grade 1—0———0——
Lymphocyte Count Decreased, Missing, Grade 2—1———1——
Lymphocyte Count Decreased, Missing, Grade 3—0———0——
Lymphocyte Count Decreased, Missing, Grade 4—0———0——
Lymphocyte Count Increased, Grade 0, Grade 100000000
Lymphocyte Count Increased, Grade 0, Grade 219310010
Lymphocyte Count Increased, Grade 0, Grade 304110000
Lymphocyte Count Increased, Grade 0, Grade 400000000
Lymphocyte Count Increased, Grade 1, Grade 000000000
Lymphocyte Count Increased, Grade 1, Grade 200000000
Lymphocyte Count Increased, Grade 1, Grade 300000000
Lymphocyte Count Increased, Grade 1, Grade 400000000
Lymphocyte Count Increased, Grade 2, Grade 000000000
Lymphocyte Count Increased, Grade 2, Grade 100000000
Lymphocyte Count Increased, Grade 2, Grade 200000000
Lymphocyte Count Increased, Grade 2, Grade 300000000
Lymphocyte Count Increased, Grade 2, Grade 400000000
Lymphocyte Count Increased, Grade 3, Grade 000000000
Lymphocyte Count Increased, Grade 3, Grade 100000000
Lymphocyte Count Increased, Grade 3, Grade 200000000
Lymphocyte Count Increased, Grade 3, Grade 400000000
Lymphocyte Count Increased, Grade 4, Grade 000000000
Lymphocyte Count Increased, Grade 4, Grade 100000000
Lymphocyte Count Increased, Grade 4, Grade 200000000
Lymphocyte Count Increased, Grade 4, Grade 300000000
Lymphocyte Count Increased, Missing, Grade 0—2———1——
Lymphocyte Count Increased, Missing, Grade 1—0———0——
Lymphocyte Count Increased, Missing, Grade 2—0———0——
Lymphocyte Count Increased, Missing, Grade 3—0———0——
Lymphocyte Count Increased, Missing, Grade 4—0———0——
Neutrophil Count Decreased, Grade 0, Grade 113301000
Neutrophil Count Decreased, Grade 0, Grade 212110000
Neutrophil Count Decreased, Grade 0, Grade 300000000
Neutrophil Count Decreased, Grade 0, Grade 402000000
Neutrophil Count Decreased, Grade 1, Grade 001010000
Neutrophil Count Decreased, Grade 1, Grade 203010000
Neutrophil Count Decreased, Grade 1, Grade 302000000
Neutrophil Count Decreased, Grade 1, Grade 400000000
Neutrophil Count Decreased, Grade 2, Grade 000000000
Neutrophil Count Decreased, Grade 2, Grade 101100000
Neutrophil Count Decreased, Grade 2, Grade 300000000
Neutrophil Count Decreased, Grade 2, Grade 400000000
Neutrophil Count Decreased, Grade 3, Grade 000000000
Neutrophil Count Decreased, Grade 3, Grade 100000000
Neutrophil Count Decreased, Grade 3, Grade 200000000
Neutrophil Count Decreased, Grade 3, Grade 400000000
Neutrophil Count Decreased, Grade 4, Grade 000000000
Neutrophil Count Decreased, Grade 4, Grade 100000000
Neutrophil Count Decreased, Grade 4, Grade 200000000
Neutrophil Count Decreased, Grade 4, Grade 300000000
Neutrophil Count Decreased, Missing, Grade 0—2———1——
Neutrophil Count Decreased, Missing, Grade 1—0———0——
Neutrophil Count Decreased, Missing, Grade 2—0———0——
Neutrophil Count Decreased, Missing, Grade 3—0———0——
Neutrophil Count Decreased, Missing, Grade 4—0———0——
Platelet Count Decreased, Grade 0, Grade 1021300100
Platelet Count Decreased, Grade 0, Grade 200000000
Platelet Count Decreased, Grade 0, Grade 300000000
Platelet Count Decreased, Grade 0, Grade 408200000
Platelet Count Decreased, Grade 1, Grade 002000000
Platelet Count Decreased, Grade 1, Grade 201010000
Platelet Count Decreased, Grade 1, Grade 301000000
Platelet Count Decreased, Grade 1, Grade 400000000
Platelet Count Decreased, Grade 2, Grade 000000000
Platelet Count Decreased, Grade 2, Grade 100000000
Platelet Count Decreased, Grade 2, Grade 300000000
Platelet Count Decreased, Grade 2, Grade 400000000
Platelet Count Decreased, Grade 3, Grade 000000000
Platelet Count Decreased, Grade 3, Grade 100000000
Platelet Count Decreased, Grade 3, Grade 200000000
Platelet Count Decreased, Grade 3, Grade 400000000
Platelet Count Decreased, Grade 4, Grade 001000000
Platelet Count Decreased, Grade 4, Grade 100000000
Platelet Count Decreased, Grade 4, Grade 200000000
Platelet Count Decreased, Grade 4, Grade 300000000
White Blood Cell Decreased, Grade 0, Grade 1119410000
White Blood Cell Decreased, Grade 0, Grade 204011000
White Blood Cell Decreased, Grade 0, Grade 300000000
White Blood Cell Decreased, Grade 0, Grade 401000000
White Blood Cell Decreased, Grade 1, Grade 005000000
White Blood Cell Decreased, Grade 1, Grade 205100000
White Blood Cell Decreased, Grade 1, Grade 300000000
White Blood Cell Decreased, Grade 1, Grade 401000000
White Blood Cell Decreased, Grade 2, Grade 001000000
White Blood Cell Decreased, Grade 2, Grade 100000000
White Blood Cell Decreased, Grade 2, Grade 301000000
White Blood Cell Decreased, Grade 2, Grade 400000000
White Blood Cell Decreased, Grade 3, Grade 000000000
White Blood Cell Decreased, Grade 3, Grade 100000000
White Blood Cell Decreased, Grade 3, Grade 200000000
White Blood Cell Decreased, Grade 3, Grade 400000000
White Blood Cell Decreased, Grade 4, Grade 000000000
White Blood Cell Decreased, Grade 4, Grade 100000000
White Blood Cell Decreased, Grade 4, Grade 200000000
White Blood Cell Decreased, Grade 4, Grade 300000000
Leukocytosis , Grade 0, Grade 100000000
Leukocytosis , Grade 0, Grade 200000000
Leukocytosis , Grade 0, Grade 300000000
Leukocytosis , Grade 0, Grade 400000000
Leukocytosis , Grade 1, Grade 000000000
Leukocytosis , Grade 1, Grade 200000000
Leukocytosis , Grade 1, Grade 300000000
Leukocytosis , Grade 1, Grade 400000000
Leukocytosis , Grade 2, Grade 000000000
Leukocytosis , Grade 2, Grade 100000000
Leukocytosis , Grade 2, Grade 300000000
Leukocytosis , Grade 2, Grade 400000000
Leukocytosis , Grade 3, Grade 000000000
Leukocytosis , Grade 3, Grade 100000000
Leukocytosis , Grade 3, Grade 200000000
Leukocytosis , Grade 3, Grade 400000000
Leukocytosis , Grade 4, Grade 000000000
Leukocytosis , Grade 4, Grade 100000000
Leukocytosis , Grade 4, Grade 200000000
Leukocytosis , Grade 4, Grade 300000000
SecondaryPart 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Basophils, To Low07000000
Basophils, To Normal or No Change1422439224651
Basophils, To High010110000
Eosinophils, To Low022210010
Eosinophils, To Normal or No Change1419229204641
Eosinophils, To High0391220000
Hematocrit, To Low4731874300
Hematocrit, To Normal or No Change1016922160351
Hematocrit, To High012300000
Lymphocytes, To Low—21—————
Lymphocytes, To Normal or No Change—00—————
Lymphocytes, To High—00—————
Erythrocytes, Mean Corpuscular Volume, To Low—0——————
Erythrocytes, Mean Corpuscular Volume, To Normal or No Change—0——————
Erythrocytes, Mean Corpuscular Volume, To High—1——————
Monocytes, To Low08200000
Monocytes, To Normal or No Change1118127152551
Monocytes, To High3631382100
Neutrophils, To Low—00—————
Neutrophils, To Normal or No Change—00—————
Neutrophils, To High—21—————
Erythrocytes, To Low4661360300
Erythrocytes, To Normal or No Change1018029163351
Erythrocytes, To High012011000
SecondaryPart 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Glucose, No Change/Decreased1422842214551
Glucose, Any increase024220000
Ketones, No Change/Decreased1318331163441
Ketones, Any increase1701371110
Occult Blood, No Change/Decreased812928153241
Occult Blood, Any increase31071271310
SecondaryPart 2B: Number of Participants With Dose Modifications of Feladilimab

Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Dose Modifications of Feladilimab
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Dose delays231510100
Dose escalations010110000
Infusion interruptions08000000
SecondaryPart 1A: Overall Response Rate (ORR)

ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 1A: Overall Response Rate (ORR)
Percentage of ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Overall Response Rate (ORR)0 (0.0 to 97.5)0 (0.0 to 97.5)0 (0.0 to 84.2)0 (0.0 to 41.0)8 (1.0 to 27.0)0 (0.0 to 13.7)0 (0.0 to 21.8)0 (0.0 to 12.8)0 (0.0 to 41.0)
SecondaryPart 1A: Disease Control Rate (DCR)

DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 1A: Disease Control Rate (DCR)
Percentage of ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
>=9 Weeks0 (0.0 to 97.5)0 (0.0 to 97.5)0 (0.0 to 84.2)43 (9.9 to 81.6)29 (12.6 to 51.1)28 (12.1 to 49.4)33 (11.8 to 61.6)22 (8.6 to 42.3)29 (3.7 to 71.0)
>=18 Weeks0 (0.0 to 97.5)0 (0.0 to 97.5)0 (0.0 to 84.2)14 (0.4 to 57.9)17 (4.7 to 37.4)24 (9.4 to 45.1)13 (1.7 to 40.5)7 (0.9 to 24.3)0 (0.0 to 41.0)
SecondaryPart 1A: Overall Survival (OS)

OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1A: Overall Survival (OS)
MonthsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Overall Survival (OS)4.3 (NA to NA)12.6 (NA to NA)14.0 (2.0 to 25.9)4.9 (3.5 to 8.0)6.7 (2.7 to 10.6)9.1 (4.0 to 12.9)9.1 (3.9 to 17.5)6.7 (5.4 to 9.2)7.3 (3.8 to NA)
SecondaryPart 1A: Progression-free Survival (PFS)

PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1A: Progression-free Survival (PFS)
MonthsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Progression-free Survival (PFS)1.2 (NA to NA)1.9 (NA to NA)2.1 (2.0 to 2.1)2.1 (1.3 to 3.9)2.0 (1.5 to 2.1)1.9 (1.6 to 3.7)2.1 (1.2 to 4.2)1.9 (1.8 to 2.1)1.9 (1.6 to 4.0)
SecondaryPart 1A: Time to Overall Response (TTR)

TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1A: Time to Overall Response (TTR)
MonthsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Time to Overall Response (TTR)————2.3 (NA to NA)————
SecondaryPart 1A: Duration of Response (DOR)

DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1A: Duration of Response (DOR)
MonthsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Duration of Response (DOR)————10.3 (NA to NA)————
SecondaryPart 2A: Overall Response Rate (ORR)

ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 2A: Overall Response Rate (ORR)
Percentage of ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Overall Response Rate (ORR)20 (0.5 to 71.6)0 (0.0 to 52.2)20 (0.5 to 71.6)25 (3.2 to 65.1)27 (6.0 to 61.0)18 (2.3 to 51.8)0 (0.0 to 97.5)0 (0.0 to 60.2)0 (0.0 to 20.6)0 (0.0 to 60.2)33 (0.8 to 90.6)50 (11.8 to 88.2)14 (4.7 to 29.5)46 (19.2 to 74.9)41 (20.7 to 63.6)0 (0.0 to 97.5)50 (6.8 to 93.2)
SecondaryPart 2A: Disease Control Rate (DCR)

DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 2A: Disease Control Rate (DCR)
Percentage of ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
>=9 Weeks20 (0.5 to 71.6)40 (5.3 to 85.3)40 (5.3 to 85.3)38 (8.5 to 75.5)27 (6.0 to 61.0)55 (23.4 to 83.3)0 (0.0 to 97.5)0 (0.0 to 60.2)19 (4.0 to 45.6)25 (0.6 to 80.6)33 (0.8 to 90.6)67 (22.3 to 95.7)58 (40.8 to 74.5)77 (46.2 to 95.0)86 (65.1 to 97.1)0 (0.0 to 97.5)50 (6.8 to 93.2)
>=18 Weeks20 (0.5 to 71.6)0 (0.0 to 52.2)20 (0.5 to 71.6)25 (3.2 to 65.1)27 (6.0 to 61.0)36 (10.9 to 69.2)0 (0.0 to 97.5)0 (0.0 to 60.2)13 (1.6 to 38.3)0 (0.0 to 60.2)33 (0.8 to 90.6)67 (22.3 to 95.7)44 (27.9 to 61.9)62 (31.6 to 86.1)73 (49.8 to 89.3)0 (0.0 to 97.5)50 (6.8 to 93.2)
SecondaryPart 2A: Overall Survival (OS)

OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2A: Overall Survival (OS)
MonthsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Overall Survival (OS)NA (1.1 to NA)5.3 (1.9 to NA)9.3 (2.2 to 23.5)18.4 (6.9 to NA)12.7 (3.8 to NA)14.6 (4.4 to NA)4.1 (NA to NA)3.0 (0.8 to 13.9)8.2 (3.1 to 10.4)6.1 (1.2 to NA)8.6 (2.2 to NA)7.5 (5.7 to 13.8)8.2 (4.9 to 12.6)18.5 (9.4 to NA)16.1 (10.5 to NA)NA (NA to NA)NA (13.2 to NA)
SecondaryPart 2A: Progression-free Survival (PFS)

PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2A: Progression-free Survival (PFS)
MonthsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Progression-free Survival (PFS)2.0 (1.1 to NA)1.9 (0.3 to 3.9)1.9 (1.8 to 6.0)2.1 (1.5 to 7.6)2.1 (1.4 to 7.2)2.0 (1.5 to 17.3)1.9 (NA to NA)1.7 (0.8 to 3.0)2.0 (1.4 to 2.1)1.6 (1.1 to 4.2)2.1 (1.7 to NA)5.7 (1.2 to 6.1)4.5 (2.6 to 6.0)6.7 (1.9 to NA)7.3 (4.1 to 10.7)1.9 (NA to NA)NA (2.1 to NA)
SecondaryPart 2A: Time to Overall Response (TTR)

TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2A: Time to Overall Response (TTR)
MonthsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Time to Overall Response (TTR)2.1 (NA to NA)—2.0 (NA to NA)2.8 (1.4 to 4.1)3.0 (1.9 to 4.0)11.0 (4.0 to 18.0)————2.1 (NA to NA)1.6 (1.3 to 1.9)2.1 (2.0 to 4.0)1.6 (1.4 to 2.8)2.1 (1.4 to 4.2)—2.1 (2.0 to 2.1)
SecondaryPart 2A: Duration of Response (DOR)

DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2A: Duration of Response (DOR)
MonthsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
Part 2A: Duration of Response (DOR)NA (NA to NA)—4.1 (NA to NA)14.3 (6.3 to 22.2)NA (3.2 to NA)13.8 (NA to NA)————NA (NA to NA)4.5 (4.2 to 4.8)22.5 (4.0 to 22.5)NA (4.9 to NA)6.0 (4.6 to NA)—NA (NA to NA)
SecondaryPart 1B: Overall Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 1B: Overall Response Rate (ORR)
Percentage of ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Overall Response Rate (ORR)5 (0.6 to 17.3)4 (1.4 to 9.9)8 (2.8 to 18.7)
SecondaryPart 1B: Disease Control Rate (DCR)

DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 1B: Disease Control Rate (DCR)
Percentage of ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
>=9 Weeks38 (23.4 to 55.4)39 (30.2 to 48.7)39 (26.5 to 52.6)
>=18 Weeks23 (11.1 to 39.3)23 (15.3 to 31.3)19 (9.7 to 30.9)
SecondaryPart 1B: Overall Survival (OS)

OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1B: Overall Survival (OS)
MonthsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Overall Survival (OS)10.5 (6.7 to 17.3)9.4 (7.9 to 12.9)7.8 (6.5 to 8.7)
SecondaryPart 1B: Progression-free Survival (PFS)

PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1B: Progression-free Survival (PFS)
MonthsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Progression-free Survival (PFS)2.1 (2.0 to 3.9)2.1 (2.0 to 2.6)2.1 (2.0 to 2.3)
SecondaryPart 1B: Time to Overall Response (TTR)

TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1B: Time to Overall Response (TTR)
MonthsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Time to Overall Response (TTR)3.0 (2.0 to 4.0)3.0 (2.0 to 3.9)3.8 (2.0 to 4.3)
SecondaryPart 1B: Duration of Response (DOR)

DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 1B: Duration of Response (DOR)
MonthsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Duration of Response (DOR)7.3 (4.2 to 10.4)11.8 (6.1 to 17.5)7.2 (6.1 to 8.2)
SecondaryPart 2B: Overall Response Rate (ORR)

ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 2B: Overall Response Rate (ORR)
Percentage of ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Overall Response Rate (ORR)7 (0.2 to 33.9)20 (14.9 to 25.0)18 (8.2 to 32.7)30 (13.2 to 52.9)0 (0.0 to 60.2)17 (0.4 to 64.1)0 (0.0 to 52.2)0 (0.0 to 97.5)
SecondaryPart 2B: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.

Time frame:
Up to approximately 367 weeks
Reported as:
Number · Percentage of Participants
Part 2B: Disease Control Rate (DCR)
Percentage of ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
>=9 Weeks29 (8.4 to 58.1)58 (52.1 to 64.5)43 (28.3 to 59.0)57 (34.5 to 76.8)50 (6.8 to 93.2)33 (4.3 to 77.7)0 (0.0 to 52.2)0 (0.0 to 97.5)
>=18 Weeks21 (4.7 to 50.8)39 (32.8 to 45.1)27 (15.0 to 42.8)35 (16.4 to 57.3)25 (0.6 to 80.6)33 (4.3 to 77.7)0 (0.0 to 52.2)0 (0.0 to 97.5)
SecondaryPart 2B: Overall Survival (OS)

OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2B: Overall Survival (OS)
MonthsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Overall Survival (OS)8.9 (3.4 to 15.6)12.5 (10.1 to 15.2)12.1 (8.9 to 19.9)10.8 (5.3 to 28.1)NA (2.3 to NA)NA (2.7 to NA)4.7 (0.5 to NA)1.1 (NA to NA)
SecondaryPart 2B: Progression-free Survival (PFS)

PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2B: Progression-free Survival (PFS)
MonthsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Progression-free Survival (PFS)2.6 (1.1 to 4.2)3.9 (2.8 to 4.0)2.3 (2.0 to 4.0)4.4 (2.1 to 6.4)2.1 (1.1 to 8.4)3.1 (1.4 to 13.7)1.5 (0.5 to 2.3)0.8 (NA to NA)
SecondaryPart 2B: Time to Overall Response (TTR)

TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2B: Time to Overall Response (TTR)
MonthsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Time to Overall Response (TTR)2.1 (NA to NA)2.1 (2.0 to 3.9)2.0 (1.3 to 2.6)2.1 (1.9 to 4.1)—2.2 (NA to NA)——
SecondaryPart 2B: Duration of Response (DOR)

DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1

Time frame:
Up to approximately 367 weeks
Reported as:
Median · Months
Part 2B: Duration of Response (DOR)
MonthsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Duration of Response (DOR)6.1 (NA to NA)13.8 (8.3 to 19.5)18.7 (4.3 to 38.0)24.6 (2.6 to 24.6)—11.5 (NA to NA)——
SecondaryPart 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab

Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours POST EOI; week 1; week 2; Pre-dose and 0.5 hours POST EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours POST EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Reported as:
Geometric mean · Microgram/millilitre (ug/mL)
Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab
Microgram/millilitre (ug/mL)Part 1A: Fela 0.003 mg/kgPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Cmax, Cycle 10.0887 ± NANA ± NA0.2038 ± 12.62531.7433 ± 90.59402.3041 ± 14.00766.4643 ± 23.798918.3809 ± 24.409374.7985 ± 16.0934193.7782 ± 17.1955
Ctau, Cycle 1NA ± NANA ± NA——0.2868 ± 62.21801.0533 ± 9.25654.3093 ± 21.603311.3112 ± 85.345938.0810 ± 22.3643
Ctau, Cycle 6NA ± NANA ± NA—0.2426 ± NA0.3510 ± NA—11.9562 ± NA—35.9660 ± NA
SecondaryPart 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Reported as:
Geometric mean · Hour*microgram/millilitre (h*ug/mL)
Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab
Hour*microgram/millilitre (h*ug/mL)Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab———134.6206 ± NA373.6877 ± 23.20531156.5768 ± 6.80314839.0026 ± NA11368.0960 ± NA—
SecondaryPart 2A: Ctau of Pembrolizumab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · ug/mL
Part 2A: Ctau of Pembrolizumab
ug/mLPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mg
Cycle 110.8032 ± 55.746119.2951 ± 41.016016.7039 ± 47.934013.9035 ± 31.906012.9277 ± 42.363415.1724 ± 40.5000
Cycle 635.1000 ± NA62.3000 ± NA—35.3321 ± 21.987735.6000 ± NA35.6444 ± 63.8554
SecondaryPart 2A: AUC (0-504h) of Pembrolizumab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · h*ug/mL
Part 2A: AUC (0-504h) of Pembrolizumab
h*ug/mLPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mg
Part 2A: AUC (0-504h) of Pembrolizumab11363.9193 ± NA——11556.7001 ± NA19158.7768 ± NA17928.7606 ± 32.2374
SecondaryPart 2A: Cmax and Ctau of GSK3174998

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · ug/mL
Part 2A: Cmax and Ctau of GSK3174998
ug/mLPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mg
Cmax, Cycle 1—5.1078 ± 27.70406.6367 ± 47.59305.5967 ± 10.545522.7767 ± 13.7397
Ctau, Cycle 1—0.6700 ± NA0.6484 ± 52.43420.5893 ± 72.06994.5862 ± 50.0449
Ctau, Cycle 6——0.5663 ± 94.4364——
SecondaryPart 2A: AUC (0-504 h) of GSK3174998

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · h*ug/mL
Part 2A: AUC (0-504 h) of GSK3174998
h*ug/mLPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mg
Part 2A: AUC (0-504 h) of GSK3174998—1038.4544 ± NA953.0313 ± 9.2381703.8874 ± 2.77234606.4365 ± 21.6164
SecondaryPart 1B: Cmax and Ctau of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Reported as:
Geometric mean · ug/mL
Part 1B: Cmax and Ctau of Feladilimab
ug/mLPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
BIOMARKER, Cmax, Cycle 1——6.9732 ± 25.8747
BIOMARKER, Ctau, Cycle 1——1.1411 ± 45.6223
BIOMARKER, Ctau, Cycle 6——2.0597 ± 61.8911
BLADDER/UROTHELIAL, Cmax, Cycle 13.2855 ± 98.786825.8491 ± 15.5203—
BLADDER/UROTHELIAL, Ctau, Cycle 10.5029 ± 151.57785.3950 ± 39.3125—
BLADDER/UROTHELIAL, Ctau, Cycle 6—13.6665 ± 21.8363—
CERVICAL, Cmax, Cycle 1—27.2607 ± 28.7319—
CERVICAL, Ctau, Cycle 1—3.8347 ± 51.9848—
CERVICAL, Ctau, Cycle 6—12.7002 ± 14.0710—
JAPAN PK/PD, Cmax, Cycle 15.8973 ± 10.955522.4768 ± 11.3862—
JAPAN PK/PD, Ctau, Cycle 11.2533 ± 9.35145.1381 ± 12.9597—
JAPAN PK/PD, Ctau, Cycle 6—10.9800 ± NA—
MELANOMA, Cmax, Cycle 16.2711 ± 24.529023.9959 ± 23.9522—
MELANOMA, Ctau, Cycle 11.2025 ± 33.06324.3924 ± 55.2035—
MELANOMA, Ctau, Cycle 62.6320 ± 46.346211.2405 ± 32.8873—
MSI-H/DMMR, Cmax, Cycle 15.4181 ± 38.599925.6766 ± 27.3384—
MSI-H/DMMR, Ctau, Cycle 10.9976 ± 41.41535.1437 ± 46.0134—
MSI-H/DMMR, Ctau, Cycle 62.5409 ± 61.51619.7769 ± 143.2225—
NSCLC, Cmax, Cycle 18.4009 ± 38.853124.2697 ± 29.1958—
NSCLC, Ctau, Cycle 11.4713 ± 39.33255.4292 ± 55.3073—
NSCLC, Ctau, Cycle 64.2630 ± NA8.6574 ± 62.7001—
VIRAL-POSITIVE, Cmax, Cycle 1—24.2995 ± 25.3201—
VIRAL-POSITIVE, Ctau, Cycle 1—5.0751 ± 45.1953—
VIRAL-POSITIVE, Ctau, Cycle 6—11.0416 ± 36.7974—
SecondaryPart 1B: AUC (0-504 h) of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Reported as:
Geometric mean · h*ug/mL
Part 1B: AUC (0-504 h) of Feladilimab
h*ug/mLPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
BIOMARKER——1076.8681 ± 27.3988
BLADDER/UROTHELIAL632.0762 ± NA5026.8004 ± 24.5736—
CERVICAL—5222.1970 ± 5.6103—
JAPAN PK/PD1237.7314 ± 9.60084525.7373 ± 5.5353—
MELANOMA1206.7402 ± 18.66794048.7261 ± 29.9449—
MSI-H/DMMR1048.2771 ± 24.61055952.2979 ± 59.1357—
NSCLC—4731.8292 ± 31.1548—
VIRAL-POSITIVE—4337.5163 ± 26.4590—
SecondaryPart 2B: Cmax and Ctau of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · ug/mL
Part 2B: Cmax and Ctau of Feladilimab
ug/mLPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
BLADDER/UROTHELIAL, Cmax, Cycle 1—7.0435 ± 16.0950——————
BLADDER/UROTHELIAL, Ctau, Cycle 1—1.1346 ± 49.2057——————
BLADDER/UROTHELIAL, Ctau, Cycle 6—2.5980 ± 39.5677——————
CERVICAL, Cmax, Cycle 1—7.8457 ± 25.623631.0460 ± NA—————
CERVICAL, Ctau, Cycle 1—1.1026 ± 86.66448.3270 ± NA—————
CERVICAL, Ctau, Cycle 6—3.5457 ± 51.568419.2960 ± NA—————
HNSCC Q6W, Cmax, Cycle 1—————12.7362 ± 35.694770.9208 ± 22.9901—
HNSCC Q6W, Ctau, Cycle 1——————6.6970 ± NA—
HNSCC RANDOMIZED, Cmax, Cycle 12.2993 ± 35.48906.8500 ± NA21.7283 ± 27.294571.1264 ± 25.9928————
HNSCC RANDOMIZED, Ctau, Cycle 10.3314 ± 75.48631.2350 ± NA4.3179 ± 32.978514.0320 ± 34.6240————
HNSCC RANDOMIZED, Ctau, Cycle 60.4949 ± 141.2509—15.0674 ± 100.453178.2867 ± 251.8571————
HNSCC_CPS<1, Cmax, Cycle 1————11.7572 ± 72.5188——39.4240 ± NA
HNSCC_CPS<1, Ctau, Cycle 1————1.4240 ± NA———
JAPAN PK/PD, Cmax, Cycle 1—7.8198 ± 7.757221.5695 ± 8.906069.9207 ± 31.4654————
JAPAN PK/PD, Ctau, Cycle 1—0.8800 ± 77.41024.3511 ± 28.127015.7566 ± 16.4440————
JAPAN PK/PD, Ctau, Cycle 6———37.7140 ± NA————
MELANOMA, Cmax, Cycle 1—8.3936 ± 43.152925.7542 ± 12.1953—————
MELANOMA, Ctau, Cycle 1—1.4839 ± 42.98084.2946 ± 47.1494—————
MELANOMA, Ctau, Cycle 6—3.2491 ± 66.90618.3404 ± 58.4213—————
MSI-H/DMMR, Cmax, Cycle 1—7.4487 ± 20.8910——————
MSI-H/DMMR, Ctau, Cycle 1—1.2458 ± 75.5891——————
MSI-H/DMMR, Ctau, Cycle 6—3.3140 ± 32.6114——————
NSCLC, Cmax, Cycle 1—8.1306 ± 47.510316.0295 ± 88.7297—————
NSCLC, Ctau, Cycle 1—1.0848 ± 63.68792.7263 ± 66.3138—————
NSCLC, Ctau, Cycle 6—3.0399 ± 53.4515——————
VIRAL-POSITIVE, Cmax, Cycle 1—7.5533 ± 20.0814——————
VIRAL-POSITIVE, Ctau, Cycle 1—1.0357 ± 66.5632——————
VIRAL-POSITIVE, Ctau, Cycle 6—1.9175 ± 77.2467——————
SecondaryPart 2B: AUC (0-504 h) of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · h*ug/mL
Part 2B: AUC (0-504 h) of Feladilimab
h*ug/mLPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 80 mg + Pembro 200 mg
BLADDER/UROTHELIAL—1205.2673 ± 24.3543————
CERVICAL—1254.7759 ± 39.2813————
HNSCC RANDOMIZED294.2888 ± 46.75921500.4305 ± NA4225.4602 ± 33.110513829.6005 ± 18.4367——
JAPAN PK/PD—1367.0149 ± 359.191954258.3090 ± 280.0809413890.8203 ± NA——
MELANOMA—1082.3162 ± 48.13864098.4237 ± 45.2413———
MSI-H/DMMR—1264.0452 ± 280.10101————
NSCLC—1318.6658 ± 664.640333071.5346 ± 1879.01269———
VIRAL-POSITIVE—1415.2121 ± 355.25950————
SecondaryPart 2B: AUC (0-1008 h) of Feladilimab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Reported as:
Geometric mean · h*ug/mL
Part 2B: AUC (0-1008 h) of Feladilimab
h*ug/mLPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mg
Part 2B: AUC (0-1008 h) of Feladilimab3829.5867 ± NA22182.5834 ± NA
SecondaryPart 2B: Cmax and Ctau of Pembrolizumab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

No measurements were reported for this outcome.

SecondaryPart 2B: AUC (0-504h) of Pembrolizumab

Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.

Time frame:
Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93

No measurements were reported for this outcome.

SecondaryPart 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level
ParticipantsPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level000003000
SecondaryPart 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level
ParticipantsPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mg
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level00100
SecondaryPart 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mg
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab100000
SecondaryPart 2A: Number of Participants With Positive Results in ADA in Pembrolizumab

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab
ParticipantsPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mg
Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab000000
SecondaryPart 2A: Number of Participants With Positive Results in ADA in GSK3174998

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Results in ADA in GSK3174998
ParticipantsPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mg
Part 2A: Number of Participants With Positive Results in ADA in GSK317499800100
SecondaryPart 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level
ParticipantsPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level0000
SecondaryPart 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
ParticipantsPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level001
SecondaryPart 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level05000000
SecondaryPart 2B: Number of Participants With Positive Results in ADA in Pembrolizumab

Serum samples collected and tested for the presence of ADA with a screening assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab
ParticipantsPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab00000000
SecondaryPart 1A: Receptor Occupancy of Feladilimab

Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Geometric mean · percent receptor occupancy
Part 1A: Receptor Occupancy of Feladilimab
percent receptor occupancyPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kg
%CD4+——74.643 ± NA25.406 ± 21.42390.229 ± 9.93296.559 ± 2.93494.007 ± 7.90499.553 ± 1.55996.030 ± 6.652
%CD8+——70.043 ± NA16.646 ± 283.34576.985 ± 16.34980.933 ± 23.48088.546 ± 10.38395.934 ± 7.15682.965 ± 29.404
SecondaryPart 2A: Receptor Occupancy of Feladilimab

Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Geometric mean · percent receptor occupancy
Part 2A: Receptor Occupancy of Feladilimab
percent receptor occupancyPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8/24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24/80 mgPart 2A: Fela 24 mg + Chemotherapy (+/-Pembrolizumab)Part 2A: Fela 80 mg + Chemotherapy (+/- Pembrolizumab)Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg
%CD4+87.351 ± 4.630—97.962 ± 2.28298.244 ± 1.88899.364 ± 1.33399.704 ± 0.99593.157 ± 1.01797.324 ± 3.75399.887 ± 0.17696.417 ± 7.17994.324 ± 36.547——
%CD8+82.973 ± 13.323—99.782 ± 4.17393.448 ± 10.62297.995 ± 3.700100.887 ± 2.26479.261 ± 4.87893.221 ± 8.14196.540 ± 4.15794.960 ± 7.366101.528 ± 18.835——
SecondaryPart 1B: Receptor Occupancy of Feladilimab

Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Geometric mean · percent receptor occupancy
Part 1B: Receptor Occupancy of Feladilimab
percent receptor occupancyPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mg
%CD4+96.520 ± 4.25899.179 ± 3.92698.128 ± 2.192
%CD8+90.111 ± 11.70096.160 ± 9.42981.219 ± 21.037
SecondaryPart 2B: Receptor Occupancy of Feladilimab

Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.

Time frame:
Up to approximately 367 weeks
Reported as:
Geometric mean · percent receptor occupancy
Part 2B: Receptor Occupancy of Feladilimab
percent receptor occupancyPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mg
%CD4+95.795 ± 4.26795.750 ± 8.75799.004 ± 1.65899.988 ± 0.82787.194 ± NA101.663 ± 2.364100.790 ± 1.198—
%CD8+89.773 ± 8.36093.581 ± 9.04996.900 ± 4.013102.610 ± 9.13857.856 ± NA106.059 ± 14.555103.802 ± 6.179—

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to approximately 367 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)1/1 (100%)0/1 (0%)1/1 (100%)
Part 1A: Fela 0.003 mg/kg1/1 (100%)0/1 (0%)1/1 (100%)
Part 1A: Fela 0.010 mg/kg2/2 (100%)1/2 (50%)2/2 (100%)
Part 1A: Fela 0.030 mg/kg7/7 (100%)2/7 (28.6%)7/7 (100%)
Part 1A: Fela 0.100 mg/kg18/24 (75%)6/24 (25%)19/24 (79.2%)
Part 1A: Fela 0.300 mg/kg17/25 (68%)8/25 (32%)23/25 (92%)
Part 1A: Fela 1.000 mg/kg11/15 (73.3%)4/15 (26.7%)12/15 (80%)
Part 1A: Fela 3.000 mg/kg21/27 (77.8%)12/27 (44.4%)17/27 (63%)
Part 1A: Fela 10.000 mg/kg3/7 (42.9%)1/7 (14.3%)6/7 (85.7%)
Part 1B: Fela 0.300 mg/kg25/39 (64.1%)9/39 (23.1%)32/39 (82.1%)
Part 1B: Fela 1.000 mg/kg69/115 (60%)44/115 (38.3%)101/115 (87.8%)
Part 1B: Fela 24 mg48/59 (81.4%)19/59 (32.2%)51/59 (86.4%)
Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg2/5 (40%)3/5 (60%)5/5 (100%)
Part 2A: Fela 0.030 mg/kg + Pembro 200 mg4/5 (80%)2/5 (40%)5/5 (100%)
Part 2A: Fela 0.100 mg/kg + Pembro 200 mg5/5 (100%)3/5 (60%)5/5 (100%)
Part 2A: Fela 0.300 mg/kg + Pembro 200 mg6/8 (75%)2/8 (25%)5/8 (62.5%)
Part 2A: Fela 1.000 mg/kg + Pembro 200 mg6/11 (54.5%)3/11 (27.3%)8/11 (72.7%)
Part 2A: Fela 3.000 mg/kg + Pembro 200 mg7/11 (63.6%)4/11 (36.4%)10/11 (90.9%)
Part 2A: Fela 8 mg + GSK3174998 8 mg1/1 (100%)0/1 (0%)0/1 (0%)
Part 2A: Fela 8 mg + GSK3174998 24 mg3/4 (75%)2/4 (50%)4/4 (100%)
Part 2A: Fela 24 mg + GSK3174998 24 mg13/16 (81.3%)5/16 (31.3%)14/16 (87.5%)
Part 2A: Fela 80 mg + GSK3174998 24 mg3/4 (75%)2/4 (50%)3/4 (75%)
Part 2A: Fela 80 mg + GSK3174998 80 mg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part 2A: Fela 24 mg + Chemotherapy4/6 (66.7%)4/6 (66.7%)6/6 (100%)
Part 2A: Fela 80 mg + Chemotherapy31/36 (86.1%)13/36 (36.1%)36/36 (100%)
Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy7/13 (53.8%)3/13 (23.1%)13/13 (100%)
Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy13/22 (59.1%)17/22 (77.3%)22/22 (100%)
Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg0/1 (0%)0/1 (0%)1/1 (100%)
Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg1/4 (25%)1/4 (25%)4/4 (100%)
Part 2B: Fela 0.100 mg/kg + Pembro 200 mg12/14 (85.7%)3/14 (21.4%)13/14 (92.9%)
Part 2B: Fela 0.300 mg/kg + Pembro 200 mg202/255 (79.2%)126/255 (49.4%)236/255 (92.5%)
Part 2B: Fela 1.000 mg/kg + Pembro 200 mg31/44 (70.5%)17/44 (38.6%)40/44 (90.9%)
Part 2B: Fela 3.000 mg/kg + Pembro 200 mg17/23 (73.9%)7/23 (30.4%)21/23 (91.3%)
Part 2B: Fela 24 mg + Pembro 200 mg2/4 (50%)1/4 (25%)4/4 (100%)
Part 2B: Fela 48 mg + Pembro 400 mg3/6 (50%)2/6 (33.3%)5/6 (83.3%)
Part 2B: Fela 160 mg + Pembro 400 mg3/5 (60%)2/5 (40%)4/5 (80%)
Part 2B: Fela 80 mg + Pembro 200 mg1/1 (100%)1/1 (100%)1/1 (100%)
Crossover: Fela 0.100 mg/kg + Pembro 200 mg1/1 (100%)0/1 (0%)1/1 (100%)
Crossover: Fela 0.300 mg/kg + Pembro 200 mg14/19 (73.7%)4/19 (21.1%)15/19 (78.9%)
Crossover: Fela 1.000 mg/kg + Pembro 200 mg32/42 (76.2%)12/42 (28.6%)26/42 (61.9%)
Crossover: Fela 3.000 mg/kg + Pembro 200 mg2/2 (100%)1/2 (50%)1/2 (50%)
Crossover: Fela 24 mg + Pembro 200 mg1/1 (100%)0/1 (0%)1/1 (100%)
Crossover: Pembro 200 mg0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 236
Most frequent serious events
EventPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgCrossover: Fela 0.100 mg/kg + Pembro 200 mgCrossover: Fela 0.300 mg/kg + Pembro 200 mgCrossover: Fela 1.000 mg/kg + Pembro 200 mgCrossover: Fela 3.000 mg/kg + Pembro 200 mgCrossover: Fela 24 mg + Pembro 200 mgCrossover: Pembro 200 mg
AstheniaGeneral disorders0/10/10/20/70/240/250/150/270/70/390/1151/590/50/50/50/80/111/110/10/40/160/40/30/60/360/130/220/10/40/142/2550/440/230/40/60/51/10/10/191/420/20/10/1
Small intestinal obstructionGastrointestinal disorders0/10/11/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/360/130/220/10/40/142/2550/440/230/40/60/50/10/10/190/420/20/10/1
OverdoseInjury, poisoning and procedural complications0/10/10/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/360/130/220/10/40/140/2550/440/230/40/60/50/10/10/190/421/20/10/1
General physical health deteriorationGeneral disorders0/10/10/20/70/240/250/150/270/70/394/1150/590/50/50/50/80/110/110/10/41/160/41/30/61/360/130/220/10/40/143/2551/440/230/40/60/50/10/10/190/420/20/10/1
PneumoniaInfections and infestations0/10/10/21/71/240/250/154/270/70/394/1150/591/50/50/50/81/111/110/10/40/160/41/30/61/360/131/220/10/40/1413/2551/440/230/40/60/50/10/11/190/420/20/10/1
Cardiac aneurysmCardiac disorders0/10/10/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/360/130/220/11/40/140/2550/440/230/40/60/50/10/10/190/420/20/10/1
Atrial septal defectCongenital, familial and genetic disorders0/10/10/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/360/130/220/11/40/140/2550/440/230/40/60/50/10/10/190/420/20/10/1
Abdominal painGastrointestinal disorders0/10/10/20/70/242/250/150/270/70/392/1150/590/50/50/50/80/110/110/10/40/161/40/30/60/360/131/220/10/40/142/2550/440/230/40/60/50/10/10/191/420/20/10/1
AscitesGastrointestinal disorders0/10/10/20/70/241/250/150/270/70/390/1151/590/50/50/50/80/110/110/10/40/161/40/30/61/360/130/220/10/40/141/2550/440/230/40/60/50/10/10/190/420/20/10/1
DysphagiaGastrointestinal disorders0/10/10/20/70/240/250/150/270/70/391/1150/590/50/50/50/80/110/110/11/40/160/40/31/60/360/130/220/10/40/141/2550/440/230/41/60/50/10/10/191/420/20/10/1
Most frequent other events
Showing 10 of 267
Most frequent other events
EventPart 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgCrossover: Fela 0.100 mg/kg + Pembro 200 mgCrossover: Fela 0.300 mg/kg + Pembro 200 mgCrossover: Fela 1.000 mg/kg + Pembro 200 mgCrossover: Fela 3.000 mg/kg + Pembro 200 mgCrossover: Fela 24 mg + Pembro 200 mgCrossover: Pembro 200 mg
Abdominal painGastrointestinal disorders1/10/11/21/73/242/252/152/271/79/399/1157/590/51/52/51/80/111/110/10/41/160/41/32/64/362/134/220/10/41/1431/2553/442/230/40/60/50/10/10/190/420/20/10/1
DiarrhoeaGastrointestinal disorders1/10/11/20/72/242/253/153/270/76/3921/1159/590/51/51/51/82/112/110/11/42/161/41/31/612/361/137/220/11/40/1446/2557/448/231/41/60/50/10/12/190/420/20/10/1
DyspepsiaGastrointestinal disorders0/11/10/20/71/240/251/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/361/130/220/10/40/140/2550/440/230/40/60/50/10/11/191/420/20/10/1
DysphagiaGastrointestinal disorders0/10/10/20/72/240/251/151/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/362/133/220/10/40/1414/2552/441/231/40/60/51/10/10/190/420/20/10/1
Irritable bowel syndromeGastrointestinal disorders0/10/10/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/160/40/30/60/360/130/220/10/40/140/2550/440/230/40/60/50/10/10/190/420/21/10/1
NauseaGastrointestinal disorders0/10/12/20/73/241/253/156/270/78/3924/1159/593/52/53/51/82/111/110/10/41/160/41/35/620/365/1311/220/11/42/1446/2557/443/230/40/60/51/10/11/197/420/20/10/1
ProctalgiaGastrointestinal disorders1/10/10/20/70/240/250/150/270/70/390/1150/590/50/50/50/80/110/110/10/40/161/40/30/60/360/130/220/10/40/140/2550/440/230/40/60/50/10/10/190/420/20/10/1
VomitingGastrointestinal disorders0/10/11/20/73/241/252/153/270/75/3918/1152/591/53/53/51/82/110/110/10/44/160/42/31/66/362/136/220/11/41/1428/2552/442/230/40/60/51/10/12/193/420/20/10/1
AstheniaGeneral disorders0/10/10/21/75/242/251/154/272/711/3927/11515/590/51/50/50/80/112/110/11/43/161/41/33/610/362/131/220/10/41/1448/25510/444/231/41/60/51/10/15/195/420/21/10/1
FatigueGeneral disorders0/11/10/22/75/244/253/156/270/75/3920/1159/591/51/55/52/81/110/110/13/41/160/41/30/68/364/1310/220/12/41/1446/2558/444/230/41/60/50/10/10/193/420/20/10/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgTotal
18 - 93 years11272425152773911559555811111416436361322141425544234651829
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgTotal
Female10141114411218472512234501803113150021151540020325
Male0113131111165216834433576138405231217141214029194631504
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg)Part 1A: Fela 0.003 mg/kgPart 1A: Fela 0.010 mg/kgPart 1A: Fela 0.030 mg/kgPart 1A: Fela 0.100 mg/kgPart 1A: Fela 0.300 mg/kgPart 1A: Fela 1.000 mg/kgPart 1A: Fela 3.000 mg/kgPart 1A: Fela 10.000 mg/kgPart 1B: Fela 0.300 mg/kgPart 1B: Fela 1.000 mg/kgPart 1B: Fela 24 mgPart 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mgPart 2A: Fela 0.030 mg/kg + Pembro 200 mgPart 2A: Fela 0.100 mg/kg + Pembro 200 mgPart 2A: Fela 0.300 mg/kg + Pembro 200 mgPart 2A: Fela 1.000 mg/kg + Pembro 200 mgPart 2A: Fela 3.000 mg/kg + Pembro 200 mgPart 2A: Fela 8 mg + GSK3174998 8 mgPart 2A: Fela 8 mg + GSK3174998 24 mgPart 2A: Fela 24 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 24 mgPart 2A: Fela 80 mg + GSK3174998 80 mgPart 2A: Fela 24 mg + ChemotherapyPart 2A: Fela 80 mg + ChemotherapyPart 2A: Fela 24 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 80 mg + 200 mg Pembro + ChemotherapyPart 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mgPart 2A: Fela 24 mg + Bintrafusp Alfa 2400 mgPart 2B: Fela 0.100 mg/kg + Pembro 200 mgPart 2B: Fela 0.300 mg/kg + Pembro 200 mgPart 2B: Fela 1.000 mg/kg + Pembro 200 mgPart 2B: Fela 3.000 mg/kg + Pembro 200 mgPart 2B: Fela 24 mg + Pembro 200 mgPart 2B: Fela 48 mg + Pembro 400 mgPart 2B: Fela 160 mg + Pembro 400 mgPart 2B: Fela 80 mg + Pembro 200 mgTotal
HISPANIC OR LATINO000000010244110000110110201001811100133
NOT HISPANIC OR LATINO1127222214237339855445810110315325341121141122639153550730
Missing00002313041300000100010010200022147010066
08

Study locations

28 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Sarasota, Florida 34232, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Nashville, Tennessee 37232-6307, United States
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3000, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Shnghai, 200126, China
  • GSK Investigational Site
    Bordeaux Cedex, 33076, France
  • GSK Investigational Site
    Lyon cedex 08, 69373, France
  • GSK Investigational Site
    Paris, 75005, France
  • GSK Investigational Site
    Villejuif cedex, 94805, France
  • GSK Investigational Site
    Siena, Toscana 53100, Italy
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Osaka, 589-8511, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Amsterdam, 1066 CX, Netherlands
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Mága, 29010, Spain
  • GSK Investigational Site
    Sevilla, 41009, Spain
09

References and documents

Publications

  • Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1751-1763. doi: 10.1002/psp4.12917. Epub 2023 Jan 31. PubMed 36642813 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jul 2023, 84 months.

Results were first posted in Dec 2024, 1 year 5 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 84 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2016
First posted
Mar 31, 2016
StartActual
Jun 23, 2016
Primary completionActual
Jul 5, 2023
CompletionActual
Jul 5, 2023
Results first posted
Dec 27, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02723955
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Jun 23, 2016
Primary completion
Jul 5, 2023
Completion
Jul 5, 2023
Results posted
Dec 27, 2024
Last update
Dec 27, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion